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ABSTRACT 
A NOVEL ROLE FOR 5-hmC IN THE REGULATION OF CANCER TESTIS 
GENE EXPRESSION IN CANCER AND MESENCHYMAL TO EPITHELIAL 
TRANSITION 
BS 
TRACT 
Sinem YILMAZ ÖZCAN 
Ph.D. in Molecular Biology and Genetics 
Supervisor: Assist. Prof. Dr. Ali O. Güre 
December 2014 
Cancer/testis (CT) genes show highly restricted expression among normal tissues, 
limited to germ cells in the testis and ovary, and  to trophoblast cells, , but are frequently 
expressed in various cancers. Other than a clear association with promoter-specific 
demethylation and histone deacetylation, the specific mechanisms by which these genes 
are expressed  are currently unknown. In this study, we tested various mechanisms 
including promoter- and region-specific epigenetic mechanisms  to gain a better 
understanding of CT gene expression.  
To better study the epigenetic mechanisms regulating CT gene expression, we 
searched for a model that dynamically expresses CT genes. As a result of preliminary 
bioinformatic efforts and literature search, we chose to study CT gene expression in 
Caco-2 spontaneous differentiation model. We showed that PAGE-2,-2B and SPANX-B 
genes were up-regulated significantly as Caco-2 cells differentiated. Differentiation was 
also characterized as a mesenchymal to epithelial transition as evidenced by the decrease 
in mesenchymal markers (Fibronectin1, Vimentin and Transgelin) and the concomitant 
increase in epithelial markers (E-cadherin, Claudin 4 and Cdx2). CT protein (SPANX-B 
and PAGE-2,-2B) positive cells were positive for epithelial protein (Cdx2), and negative 
for mesenchymal proteins (Fibronectin1, Vimentin). Although we could not find a 
significant difference in promoter proximal DNA demethylation of CT genes, we 
identified that promoter proximal DNA was hydroxymethylated with a gradual increase 
in hydroxymethylation as cells differentiated. The change in hydroxymethylation level 
was concordant with an increase in TET enzyme levels and co-localization of TET2 
protein with CT proteins in the corresponding cells. Besides, we found that promoters of 
CT genes lost EZH2, H3K27me3 and HP1 marks as CT genes were up-regulated. 
Reversal of differentiation resulted in loss of CT and TET gene expression and EMT 
induction. Thus, for the first time, we describe dynamic expression of CT genes in 
association with DNA hydroxymethylation in mesenchymal to epithelial transition. 
In addition to promoter-proximal alterations, we thought that epigenetic alterations 
leading to CT gene expression in cancer could occur within larger regions containing CT 
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genes, but with clear boundaries. As genes that do not show an expression pattern 
similar to CT genes can be located within their proximity, we hypothesized that there 
could be clear boundaries between neighbouring regions containing CT genes and those 
with non-CT type expression patterns. We, therefore, identified 2 genes; ALAS2 and 
CDR1, in close proximity to two different CT genes (PAGE-2,-2B and SPANX-B), which 
were downregulated  in cancer, and thus showed an expression pattern opposite to that 
of these two CT genes. ALAS2 and CDR1 were downregulated in lung and colon cancer 
cell lines compared to healthy counterparts. We found that the downregulation of ALAS2 
and CDR1 in cancer  cell lines, in contrast to CT genes, was independendent of DNA 
hypomethylation. We also found that ALAS2 and CDR1 downregulation in cancer was 
possibly related to decreased  levels of hydroxymethylation in promoter proximal 
regions. As the upregulation of PAGE-2,-2B and SPANX-B genes was associated with 
increased hydroxymethylation at promoter-proximal regions, these two groups of genes, 
despite their close proximity were found to be controlled inversely albeit possibly by the 
same mechanisms. We tested if ectopic upregulation of ALAS2 and CDR1 in cancer cell 
lines would result in a tumor-suppressive effect, but were unable to find any. As both 
genes are located about 200 and 50 kbs from SPANX-B and PAGE-2, we propose that 
the there might be a boundary within these regions that could possibly have an insulator-
like function to help distinguish the two very different epigenetic events occuring in 
tumorigenesis. 
As almost all CT genes map within highly homologous inverted repeats it is possible 
that 3 dimensional chromosomal structures formed around these repeats underlie the 
common  epigenetic mechanism responsible for  coordinate CT gene expression. To test 
for this hypothesis, we analyzed expression of various transcripts identified within and 
outside the NY-ESO-1 repeat region. However, we could not find a correlation between 
the presence of such transcripts and CT gene expression patterns.   
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ÖZET 
KANSERDE VE MEZENKİMALDEN EPİTELE GECİŞ SÜRECİNDE  
5-hmC’NİN KANSER TESTİS GEN İFADESİNDEKİ ÖZGÜN ROLÜ 
0.1ABSTRACT 
Sinem YILMAZ ÖZCAN  
Moleküler Biyoloji ve Genetik Doktora Tezi 
Tez Yöneticisi: Yard. Doç. Dr. Ali O. Güre 
Aralık 2014 
Kanser testis (KT) genleri normal dokular içinde sınırlı şekilde sadece 
yumurtalık ve testislerdeki eşey üreme hücreleri ve trofoblast hücrelerinde ifade 
edilirken, pek çok kanserde sıklıkla ifade edildiği gözlenmiştir. Promotor bölgesine özgü 
DNA demetilasyonu ve histon deasetilasyonuyla ilgili açık bir ilişki haricinde bu 
genlerin ifade edilmesindeki spesifik mekanizmalar bilinmemektedir. Bu calışmada KT 
gen ifadesini daha iyi anlayabilmek icin KT genlerini bulunduran promoter bölgelerine 
özgü ve alana sınırlı epigenetik mekanizmaları test ettik.  
KT gen ifadesi varliginda ve yokluğundaki epigenetik mekanizmalari daha iyi 
calışabilmek için, KT genlerini dinamik olarak ifade eden bir model aradık. Öncü 
biyoinformatik analizler ve literatür araştırması sonucunda, KT genlerini Caco-2 
farklılaşmasında  incelemeyi seçtik. PAGE-2,-2B ve SPANX-B gen ifadelerinin 
farklılaşan Caco-2 hücrelerinde anlamlı şekilde arttığını gösterdik. Mezenkimal belirteç 
gen ifadeleri (Fibronectin1, Vimentin ve Transgelin) azaldığı ve eş zamanlı olarak epitel 
belirteç gen ifadeleri (E-cadherin, Claudin 4 ve Cdx2) arttığı için farklılaşma 
mezenkimalden epitele geçiş süreci olarak tanımlanmıştır. Bunun yanısıra, KT 
proteinlerini (SPANX-B ve PAGE-2,-2B) bulunduran hücrelerin epitel belirteç 
proteinini (CDX2) de bulundurduğu, mezenkimal belirteç proteinlerini (Fibronectin1 ve 
Vimentin) de bulundurmadığını gösterdik. Farklılaşmış Caco-2 hücrelerinde artan KT 
genlerinin promotor yakınındaki DNA bölgelerinde anlamlı demetillasyon 
gözlemlenmemekle birlikte bu bölgelerde hidroksimetilasyon seviyelerinde aşamalı bir 
artış tespit edilmiştir. Promotor yakını bölgelerdeki hidroksimetilasyon seviyesindeki 
artış aynı zamanda TET enzim seviyesindeki artış ile ve de TET2 proteini ve KT 
proteinlerinin aynı hücrelerdeki konumlanması ile uyumlu bulunmuştur. Bunların 
yanısıra, KT gen ifadesi ile birlikte KT genlerinin promotor bölgelerindeki EZH2 ve 
HP1 proteinlerinin işgali  ve H3K27me3 işareti azalmıştır. Caco-2 farklılaşması tersine 
döndürüldüğünde KT ve TET gen ifadelerinin azalması ve epitelden mezenkimale geçiş 
ile sonuçlanmıştır. Böylece bu calışma ile ilk defa KT genlerinin dinamik ifadesi 
gösterilmiş, bu süreç mezenkimalden epitele geçiş ve DNA hidroksimetilasyonu ile 
açıklanmıştır.  
vii 
 
Promotor yakını bölgelerdeki değişimlerin yanısıra, kanserde KT gen ifadesine 
sebep olan epigenetik değişikliklerle alternatif epigenetik değişikliklerin aynı anda 
sınırları belli farklı bölgelerde meydana geldiğini düşündük. KT genleri ve KT genlerine 
komşuluk eden ama KT gen ifade paterninden farklı gen ifadesine sahip olan genler 
arasında sınırlar olabileceğini hipotezledik. Boylece, KT genlerine (PAGE-2,-2B ve 
SPANX-B) komşuluk eden ve kanserde gen ifadesi azalan 2 geni, ALAS2 ve CDR1’i, 
bulduk. ALAS2 ve CDR1 gen ifadelerinin sağlıklı dokulara kıyasla kolon ve akciğer 
kanseri hücre hatlarında azaldığını gösterdik. ALAS2 ve CDR1 gen ifadelerinin kanser 
hücre hatlarındaki azalışlarının KT gen ifadesinden farklı olarak DNA metilasyonundan 
bağımsız oldugunu bulduk. Kanserde ALAS2 ve CDR1 gen ifadesi azalışlarının promotor 
yakını bölgelerdeki artan hidroksimetilasyon seviyesi ile kuvvetli ihtimal ilişkili 
olabileceğini gözlemledik. PAGE-2,-2B ve SPANX-B gen ifadelerindeki artış da DNA 
hidroksimetillasyonu ile ilişkili bulunmustur, bu iki grup genlerinin farklı ifade 
paternlerine rağmen. Kanser hücre hatlarındaki ALAS2 ve CDR1 gen ifadelerinin çarpıcı 
azalışına rağmen, bu genlerin kanser hücrelerindeki ektopik ifadeleri sonucu hücre 
canlılığı ölçümlerinde anlamlı bir değişiklik bulunmamıştır. ALAS2 ve CDR1, sırasıyla 
PAGE-2,-2B ve SPANX-B genlerine 200 ve 50 kbs uzaklıkta konumlandığından, bu 
bölgeler arasında farklı epigenetik olayların meydana gelmesinde etkili yalıtkan bir sınır 
bulunduğunu önermekteyiz.  
KT genlerinin neredeyse tamamı yüksek homolojik benzerliği bulunan tekrar 
bölgelerinde konumlandığından, bu tekrar bölgelerinin katlanarak 3 boyutlu yapılar 
oluşturması ve bu yapıların eş güdümlü KT gen ifadesinden sorumlu mekanizma olması 
muhtemeldir. Bu hipotezi test etmek icin, NY-ESO-1 genini içeren tekrar bölgesinin 
içindeki ve dışındaki genlerin ifadesini inceledik. Ancak anlamlı bir ilişki tespit 
edemedik.  
   
 
Anahtar sözcükler: Kanser testis genleri, PAGE-2,-2B, SPANX-B, DNA 
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1 INTRODUCTION 
1.1 CANCER TESTIS GENES 
 
 1.1.1 Expression Patterns of Cancer Testis Genes  
Cancer testis (CT) antigens are tumor-associated antigens that are activated in 
various human tumors from different origins. Cancer testis antigen gene expression is 
restricted to germ cells in testis and ovary and in trophoblast cells among healthy tissues 
[1]. Due to the aberrant gene expression in cancer and the restricted expression pattern in 
healthy tissues, CT genes are considered as a model to study epigenetic mechanisms 
behind gene expression and complex gene regulation processes.  
Up to now, more than 140 CT genes belonging to at least 70 gene families have 
been identified by different methodologies such as T-cell epitope cloning, serological 
analysis of recombinant cDNA expression libraries and representational difference 
analysis [2,3].   
CT genes have variable expression in different types of cancer. Melanoma, 
ovarian, bladder and non-small cell lung cancers have high CT gene expression, whereas 
breast and prostate cancers have moderate CT gene expression. Hematological 
malignancies such as lymphomas and leukemia, renal, colon and pancreatic cancers 
were identified as low CT expressing cancers[4] [5]. By using genome wide survey 
expression for 153 CT genes in normal and cancer expression libraries, Hofmann et al. 
classified CT genes in 3 groups; testis-restricted, testis/brain restricted and testis 
selective [6].  
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Figure 1.1.1 1: The expression pattern of CT-X genes in normal tissues and cancer 
CT genes on chromosome X are mainly expressed in testis and placenta among normal 
tissues. CT-X gene expression is detected in brain and in some of the normal tissues at 
very low levels albeit. Various CT genes are induced and detected in cancer tissues. 
Adopted from [6]. (Hofmann et al. PNAS, 105, 51, 2008 Genome-wide analysis of 
cancer/testis gene expression. Copyright (2008) National Academy of Sciences, U.S.A.) 
 
Gure et al. found that the analyzed nine CT genes (LAGE1, NY-ESO-1, MAGE-
A1, MAGE-A3, MAGE-A4, MAGE-A10, CT7, SSX2 and SSX4) were coordinately 
expressed in non-small cell lung cancer. According to the study, the frequency of 
expression of a second CT antigen by a tumor already expressing a CT antigen was 
higher than the expression frequency if these two events were independent. The study 
also showed significant correlation between CT expression and larger tumours’ and later 
stages of disease [7]. The associations between CT expression and different variables 
such as metastatic disease, poor survival and advanced tumour type have been 
established in many studies [5]. 
It has been previously shown that CT genes except SPAN-X were expressed in 
earlier stages of spermatogenesis such as spermatogonia and primary spermatocytes. CT 
gene expression seen at oogonia was similarly in the earlier stages of oogenesis. In the 
later stages of both spermatogenesis and oogenesis, CT gene expression was diminished 
[8]. 
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 1.1.2 Genomic Structure of Cancer Testis Genes 
Cancer testis genes can be classified as the ones encoded from Chromosome X, 
CT genes and the ones encoded from chromosomes other than Chromosome X, non-CT 
genes. Most of the CT genes are members of multigene families and each family is 
composed of proximally located and highly homologous genes that vary from 3 (NY-
ESO) to more than 12 (MAGE) genes. The multigene families exist on well-defined 
clusters that either form a direct or inverted repeat on Chromosome X [4,5]. In 2004, 
Warburton and his colleagues published the first genome wide inverted repeat structure 
of human genome identified by a software package named Inverted Repeat Finder 
program. The most dramatic result they obtained was the abundance of large and highly 
homologous inverted repeat regions containing CT genes on chromosome X. 10 of 20 
inverted repeats that they identified on X-chromosome contained a gene  expressed in 
testis tissue [9]. Since inverted repeats have the capacity to form self organizing loops 
and is a common property of majority of CT genes, the possible roles of repeats and loop 
formation on gene expression is an important question.The effect of the repeat structure 
on gene expression was proposed by Bredenbeck et al. They showed that gene 
expression inside the repeat region was coordinated compared to the gene expression 
outside the repeat region coding MAGEA and CSAG genes [10]. A direct physical link 
between gene expression and repeat structure, however, is still to be identified.  
 
1.1.3 Epigenetics of Cancer Testis Genes 
CT gene expression regulation is primarily epigenetic in nature. As well as 
promoter DNA hypermethylation in normal somatic tissues lacking CT gene expression, 
promoter DNA hypomethylation of CT genes in various CT expressing tumors have 
been shown in various studies. Induction of CT genes with the DNA hypomethylating 
agent, 5-aza-2`-deoxycytidine (5-AZA), in cancer cell lines is an important evidence of 
DNA methylation as a leading epigenetic mechanism controlling CT gene expression 
[1,11-15]. In addition to promoter and proximal promoter DNA hypomethylation, CT 
gene expression is associated with global DNA hypomethylation when MAGEA11 
expression and LINE1 methylation are studied [16]. The DNA methylation status of CT 
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genes shows intra- and inter-tumour heterogeneity [14,15]. Thus the clinical usages of 
DNA methylation inhibitors have importance in CT based immunotherapy studies. Role 
of histone acetylation in CT gene expression was revealed with synergistic effects of 
histone deacetylase inhibitors with DNA hypomethylating agent [11,17]. Recently role 
EZH2 and histone methylation on the expressions of GAGE and MAGE genes was 
presented in breast cancer cell lines. S-adenosylhomocysteine hydrolase inhibitor named 
3-deazaneplanocin was previously shown to disrupt EZH2 complex. The combination of 
DNA hypomethylating agents with 3-deazaneplanocin resulted with enhancing 
expressions of GAGE and MAGE type CT genes [18].  In another study the inhibition of 
histone methyltransferase (KMT6) and histone demethylases (KDM1 and KDM5B) 
improved the effect of DNA hypomethylating agent deoxyazacytidine on expressions of 
NY-ESO-1, MAGE-A1 and MAGE-A3 genes in lung cancer cell lines. Thereby, 
incorporation of histone methylation in epigenetic regulation of CT genes was verified 
[19]. The synergistic effect of histone methylation and DNA demethylation was shown 
recently with the combined treatment of DNMT inhibitor and LSD1 inhibitor. LSD1 
inhibitor inhibited demethylation of H3K4me2 and H3K4me1 and could synergistically 
activate CT gene expression when used with DNMT inhibitor[20]. The dominant 
function of DNA methylation in CT gene expression mechanisms compared to histone 
marks was suggested in works of De Smet et al. They generated a methylated 
MAGEA1/hph construct that was resistant to hygromycin upon stable re-activation. By 
either treating the generated clone with histone acetyltransferase inhibitor or by 
depleting  DNA methyltransferase-1, they showed hygromycin resistant cells developed 
DNA hypomethylation and active histone marks[21] 
 The transcription factor BORIS was established as a candidate for the regulation 
of CT genes. The occupancy of BORIS in NY-ESO-1 promoter was associated with gene 
expression [22]. The induction of BORIS resulted in the induction of MAGE-A3 and 
MAGE-A1 genes [23,24]. However in another study, BORIS overexpression with an 
adenoviral system did not induce CT genes, neither were promoter and global DNA 
demethylation levels altered [25]. Thus the role of BORIS in CT gene expression is 
controversial.   
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1.1.4 Cancer Testis Gene Expression in Stem Cells 
CT gene expression in stem cells and whether CT genes have a role in stem cell 
differentiation pathways are interesting questions. Expression of various CT genes 
(NRAGE, NY-ESO-1, MAGE-1 and SSX) has been detected in undifferentiated 
mesenchymal stem cells [26,27].  In addition to the CT gene expression in mesenchymal 
stem cells, melanoma and glioma cancer stem cells also express many CT genes 
(MAGE, GAGE, NY-ESO-1 and SSX families) according to different studies[28-30].  
CT gene expression (SSX, NY-ESO-1 and N-BAGE) was observed in 
undifferentiated mesenchymal stem cells (MSC). CT gene expression was attenuated as 
MSCs differentiate to adipocytes and osteocytes [31]. In addition to MSCs, expressions 
of MAGE-D1,-D2 genes in human embryonic stem cells (hESC) and expressions of 
GAGEs, MAGE-A3,-A6,-A4,-A8 genes in human embryoid body cells were described by 
Lifantseva et al.[32]. In contrast, Loriot et al. showed that various CT genes either had 
very low or no expression in human embryonic cell lines compared to melanoma cell 
lines and testis by Q RT-PCR[33]. Whether CT gene expression being present in hESCs 
is controversial, the expression of CT genes in cancer stem cells (CSC) was 
demonstrated by showing the expression of MAGED3, -D1, IL13RA, SPANXA and 
SPANXC in CD133 and SOX2 positive CSCs derived from glioma cells lines and tissues 
[30].  
1.1.5 Cancer Testis Gene Expression during Epithelial to Mesenchymal 
Transition 
 The relation between CSCs and epithelial to mesenchymal transition (EMT) 
process was characterized by Mani et al. EMT was induced in non-transformed 
immortalized human mammary epithelial cells (HMLEs) either by ectopically 
expressing Snail or Twist or TGFβ1 exposure. These cells started to resemble 
mesenchymal cells by expressing mesenchymal markers (N-cadherin, Vimentin, 
Fibronectin) and down-regulating epithelial markers (E-cadherin) and gained the ability 
to form mammospheres which was highly observed in human breast CSCs. EMT 
induced HMLEs was enriched in CD44
high
/CD24
low
 population showing a strong 
association with normal human breast epithelial stem cells and human breast CSCs. The 
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study was further improved by establishing the high expression levels of mesenchymal 
markers and the low expression levels of epithelial markers in CD44
high
/CD24
low
 cells 
isolated from patient tissue samples. [34] 
 According to these two observations; CT gene expression in glioma CSCs and 
the association of EMT with CSCs, there might be a connection between CT gene 
expression and EMT phenotype.   
 In literature, there were two papers confirming the relation of CT gene 
expression with EMT process. Contrary to the expectation, both of them claimed that CT 
gene expression was associated with the epithelial phenotype but not the mesenchymal 
phenotype in EMT. In the study conducted by Gupta et al., the gene expression in 
transformed HMLE in response of either salinomycin (shown to be effective on 
mesenchymal type of cells in tumor) or paclitaxel (shown to be effective on epithelial 
type of cells in tumor) was analyzed. MAGE-A1 gene was up-regulated in salinomycin 
treatment which eliminated the mesenchymal cells and down-regulated in paclitaxel 
treatment which eliminated the epithelial cells [35]. Similarly, the result of another study 
done by Thomson et al. claimed that CT (SPANXA1,-A2, SPANX-B1,-B2, SPANXC, 
MAGEA8, SOX2) gene expression was diminished in two EMT models generated by 
stable transfection of Snail gene and TGF-β exposure[36].   
The up-regulation of MAGE-A1 gene in epithelial enriched population and the 
down-regulation of various CT genes in two important EMT models proved that CT 
gene expression might be related with epithelial phenotype in EMT.      
 
1.2 CACO-2 SPONTANEOUS DIFFERENTIATION MODEL 
 
To associate CT gene expression with epithelial phenotype of a cell, we used 
Caco-2 spontaneous differentiation model. Caco-2 and HT29 cell lines were derived 
from colorectal tumors and well known with their capabilities to differentiate into 
mature intestinal cells, such as enterocyte, mucus and M cells. Because of their 
differentiation potential, they became important tools for in vitro structural and 
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functional studies of the intestine cells  [37].  At low seeding density, Caco-2 cells 
exhibit proper cell division and generate  normal unpolarized and undifferentiated cells 
[38]. Under standard culture conditions and upon cell to cell contact formation, in 20 to 
30 days differentiation process starts. Caco-2 cells stop dividing and become a 
monolayer of polarized epithelial cells. In addition to tight junctions, apical and basal-
lateral membranes appear and cells resemble to polarized enterocytes both in structural 
and functional manner. Even though Caco-2 cells are derived from colon, they express 
hydrolyase enzymes and transport ions and water similar to enterocytes do [39]. It is 
important to note that although Caco-2 cells are valuable model for mimicking the 
differentiation taking place from crypts to villus, these cells are malignant and belonging 
to colon tissue but not small intestine [37].  
In order to identify this model in depth and identify the transcriptional regulation 
during the enterocytic differentiation, two important studies have been done by Halbleib 
and Sääf et al. Caco-2 differentiation was generated by growing the cells on permeable 
filter supports for 26 days in this study. As well as the microscopic investigation, 
microarray experiments performed with RNAs isolated at different time points during 
differentiation were used for clarification of the differentiation process. Halbleib et al. 
showed that as well as apical brush border assembly (such as myosin 1A), many other 
proteins required for epithelial junctional complexes (Occludin, Claudin 1, 
protocadherins and desmosomal cadherins,) were regulated in transcriptional levels. The 
transcriptional regulation in some of extracellular matrix proteins (Laminin-1, Laminin-
5), and intermediate filament proteins (Keratin-20, Keratin-18) were also established. 
This study claimed that the transcriptional regulation had an important role on Caco-2 
cells being differentiate into a fully functional enterocyte in vitro without the effect of 
stromal cells and signals normally present in vivo[40]. In the other study carried by Sääf 
et al., according to microarray data there were two distinct clusters named 
prepolarization (samples from 0 to 4 days) and polarization cluster (samples from 4 to 
26 days) which were formed by the difference in gene regulation at day 4. When the 
gene expression pattern during Caco-2 differentiation was compared with normal colon 
and colorectal cancer samples, there were two clusters; tumor and normal epithelial 
cluster. While prepolarized cells remained in tumor clusters, polarized cells remained 
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normal epithelial cluster. Several genes belonging to cell cycle checkpoints, ECM 
components, Wnt pathway were shown to be differentially regulated between tumor and 
normal epithelial cluster. As a result of this study, it has been established that 
differentiated Caco-2 cells resemble more to a normal epithelial cell than a tumor cell 
[41].           
 
Figure 1.2 1: Differentially expressed genes in Caco-2 spontaneous differentiation.  
When the gene expression analysis is performed in Caco-2 spontaneous differentiation, 
there is a dramatic switch in gene expression pattern at day 4 time point. The 
undifferentiated Caco-2 cells (Day0-2) cluster with colon cancer and the differentiated 
Caco-2 cells (Day4-26) cluster with normal colon tissue.  Adopted from [41].  
 
 
1.3 DNA HYDROXYMETHYLATION AS EPIGENETIC CONTROL 
MECHANISMS OF GENE EXPRESSION 
 
 With the identification of 5-hydroxymethylcytosine (5-hmC) residue in Purkinje 
neurons and embryonic stem cells, 5-methylcytosine (5-mC) has become no more the 
only epigenetic modification of DNA [42,43]. This was groundbreaking information in 
epigenetics. 5-hyroxymethylcytosine was established as an epigenetic mark on DNA due 
to its binding partners and unique distribution patterns affecting gene expression with 
the following studies [43-45] . 5-hmC was shown to inhibit binding of methyl CpG 
binding protein 2 (MeCP2) to DNA thereby acting oppositely to 5-mC [46]. In addition 
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to inhibiting MeCP2 binding, 5-hmC has its own binding partners.  5-hmC was found to 
interact with Mbd3, a chromatin regulator, and this interaction was necessary for Tet1 
binding to chromatin and interacting with Mbd3. It was also shown that Mbd3 
preferably binds to 5-hmC compared to 5-mC [44].  When the genomic distribution of 5-
hmC was investigated in ESCs, it was identified that 5-hmC mainly localized at gene 
rich, low to moderate CpG containing regions specifically transcription start sites, 
promoters and gene bodies.  The bivalent domains containing both permissive 
H3K4me3 and repressive H3K27me3 marks were also enriched for 5hmC residues. The 
role of 5hmC on gene expression was described as activating mainly [43,45,47].  
Although recent study claimed that 5hmC could also act as inhibiting transcription in the 
case of being on distal regulatory sites such as enhancers [48]. 
Ten eleven translocation family proteins (TET1,-2 and -3) produce 5-
hydroxymethylcytosine from 5-methylcytosine. [42,49].  TET enzymes further oxidize 
and generate 5-formylcytosine and 5-carboxycytosine and 2-oxoglutarate and Fe
+2
 are 
necessary cofactors for the oxidation reaction [50].  
 Though 5-hmC is a newly identified residue, its level in human tissues is more 
than the expected levels. Brain, kidney, liver and colorectal tissues have higher 5-hmC 
levels and the abundance of 5-hmC declines in the cancerous state [51,52].  Proper 
functioning of TET enzymes and the level of 5hmC on DNA are very crucial since 
various mutations of TET2 were reported in hematological malignancies [53].  
In addition to its epigenetic functions, 5hmC also act as an intermediate player in 
DNA demethylation. It exerts its function via two different paths, passive and active 
DNA demethylation. In passive mechanism, the generated 5hmC from 5mC cannot be 
recognized by DNMT1, thereby after each cell division cycle DNA become more 
demethylated [54]. Though in some circumstances cells need to demethylate DNA 
immediately such as after fertilization or in primordial germ cells [55]. In this case 5-
hydroxymethylated cytosine residues are either further oxidized to 5-carboxylcytosine 
by TET enzymes or deaminated to 5-hyroxymethyluracil by AID/APOBEC enzymes. 
Then both 5-carboxylcytosine and 5-hydroxymethyluracil are removed from DNA by 
base excision repair mechanism (BER) [55,56].   
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Figure 1.3 1: Active DNA demethylation 
TET enzymes oxidize 5-methylcytosine to 5-hydroxymethylcytosine, 5-formylcytosine 
and 5-carboxycytosine sequentially. 5-formylcytosine and 5-carboxylcytosine is excised 
by thymine DNA glycosylase (TDG) and cytosine is added with base excision repair 
(BER) mechanism. In addition, 5-hydroxyuracil can be generated from 5-hydroxymethyl 
with AID and APOBEC mediated deamination. 5-hydroxyuracil is further be excised 
with TDG or SMUG and cytosine is added via BER.   Adopted from [45].  
 
 
 
Figure 1.3 2: Passive DNA demethylation 
5-hydroxymethylated cytosine inhibits binding of UHRF1 or DNMT1 or both UHRF1 
and DNMT1, thereby by each cell division methylated cytosines are lost. Adopted from 
[45].  
All TET enzymes have the ability to hyroxymethylate DNA; however their 
differential roles were established. In a study done in embryonic germ cell lines (EGCs), 
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TET1 was essential for the proper methylation of imprinted control regions whereas 
TET2 was indispensable for the precise reprogramming  when ECGs were fused with B 
cells [57]. The activities of TET1 on transcription start sites and TET2 on gene bodies 
were established with the gene depletion study performed in mouse embryonic stem 
cells [58]. TET1 and TET2 deficient double knockout mouse model established TET3 
have redundant functions since double knockout animals were viable though having 
decreased 5hmC levels and impaired imprinting [59].  
 New functions and novel interactions about the transcriptional role of 5hmC are 
emerging. Recently, enrichment of 5hmC on the gene bodies of neuronal genes in 
accompany with loss of H3K27me3 was shown to be essential for neurogenesis [60].  
TET2 and TET3 were shown to directly interact with O-GlcNAc transferase (OGT). 
TET2-OGT and TET2/TET3-OGT interactions resulted with O-GlcNAcylation of H2B 
Ser112 and HCF1 which is a component of H3K4 methyltransferase SET1/COMPASS 
complex respectively [61,62].  OGT was shown to interact with TET3 and O-
GlcNAcylated TET3. The modified TET3 exported to nucleus and its catalytic activity 
was inhibited [63].  
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1.4 AIM AND HYPOTHESIS 
  
Because of their unique cancer-specific expression pattern, studying the 
regulation of CT gene expression can help reveal the deregulated epigenetic mechanisms 
during carcinogenesis. Additionally, CT genes can be used as perfect biomarkers for 
DNA hypomethylation known to occur in cancer. They might be useful in the detection 
and prognosis of cancer as well.   
   In this study, we aimed to study both region specific as well as promoter-
proximal epigenetic alterations in CT gene expression in cancer. To be able to study the 
epigenetic basis of CT gene expression, we had three different approaches. In the first 
approach, we used a model dynamically expressing CT genes; thereby we studied and 
verified the responsible epigenetic mechanisms relevant to the transition from CT 
negative to positive gene expression. In the second approach, we studied CT and CT 
proximal regions with opposite expression patterns in healthy and cancer conditions. 
Finally we tried to find out an explanation to coordinate CT gene expression in cancer 
by analyzing CT encoding repeat regions on DNA since repeat demethylation was a 
known epigenetic event during carcinogenesis.    
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2 MATERIALS AND METHODS 
 
2.1 MATERIALS 
 
2.1.1 General Chemicals 
General laboratory chemicals such as; Methanol, Ethanol, Isopropanol, 
Chloroform, Formaldehyde, NaCl, tris-base, glycine are analytical grade and purchased 
from either Sigma-Aldrich (St. Louis, USA) or Calbiochem Merck Millipore 
(Darmstadt, Germany). The detailed list of the chemicals and kits were shown below. 
Table 2.1.1 1:  List of chemicals enzymes kits 
Name 
Catalog 
number 
Company 
TRIzol reagent  15596018 
Ambion by Life Sciences 
(CA, USA)  
Nuclease free water AM9930 
Ambion by Life Sciences 
(CA, USA) 
DNA-free™ Kit 
DNase Treatment and Removal 
Reagents 
AM1906 
Ambion by Life Sciences 
(CA, USA) 
RevertAid First Strand cDNA 
Synthesis Kit 
# K1622 
Thermo Scientific Inc. (IL, 
USA) 
DyNAzyme II DNA Polymerase # F-501S 
Thermo Scientific Inc. (IL, 
USA) 
OneTaq Hot Start DNA Polymerase M0481S New England BioLabs Inc.  
SYBR® Green PCR Master Mix 4309155 Applied Biosystems by Life 
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Sciences (CA, USA) 
TaqMan® Universal PCR Master 
Mix 
4364338 
Applied Biosystems by Life 
Sciences (CA, USA) 
Proteinase K P2308 
Sigma Aldrich (St. Louis, 
USA) 
Phenol:Chloroform:IAA, 25:24:1, pH 
6.6 
AM9730 
Ambion by Life Sciences 
(CA, USA) 
EZ DNA Methylation-Gold™ Kit 
(Bisulphite Conversion kit) 
D5006 Zymo Research (CA, USA) 
TA Cloning® Kit, with pCR™2.1 
Vector, without competent cells 
 
K2020-40 
Invitrogen by Life Sciences 
(CA, USA) 
Phusion® High-Fidelity DNA 
Polymerase 
 
M0530S New England BioLabs Inc. 
BamHI R0136S New England BioLabs Inc. 
NotI R0189S New England BioLabs Inc. 
XbaI R0145S New England BioLabs Inc. 
HindIII R0104S New England BioLabs Inc. 
EcoRI R0101S New England BioLabs Inc. 
T-REx™ System K1020-01 Invitrogen by Life Sciences 
Lipofectamine® 2000 Transfection 
Reagent 
11668-027 
Invitrogen by Life Sciences 
(CA, USA)  
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TransIT-LT1 Transfection Reagent MIR 2304 Mirus Bio  (Madison, USA) 
β-Gal Staining Kit 
 
K1465-01 
Invitrogen by Life 
Sciences(CA, USA)  
Cell Proliferation Kit I(MTT) 11 465 007 001 
Roche Applied Science 
(Basel, Switzerland) 
FspI R0135S New England BioLabs Inc. 
EpiSeeker hydroxymethylated DNA 
Immunoprecipitation (hMeDIP) Kit  
 
ab117134 Abcam (UK) 
UltraCruz™ Mounting Medium 
sc-24941 
 
Santa Cruz Biotechnology 
(Texas, USA) 
NuPAGE® Novex® 4-12% Bis-Tris 
Protein Gels, 1.5 mm, 15 well 
 
NP0336BOX 
NuPAGE® Novex®  by 
Life Sciences (CA, USA) 
Immobilon-P Membrane, PVDF, 
0.45 µm, 26.5 cm x 3.75 m roll 
 
IPVH00010 
Merck Millipore (MA, 
USA) 
Clarity™ Western ECL Substrate 170-5060 Bio Rad (CA, USA) 
5-aza-2-deoxycytidine A3656 
Sigma Aldrich (St. Louis, 
USA) 
Protease inhibitor cocktail P8340 
Sigma Aldrich (St. Louis, 
USA) 
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QIAquick Gel Extraction Kit  28706 QIAgen (CA, USA) 
QIAGEN Plasmid Mini Kit 12125 QIAgen (CA, USA) 
QIAGEN Plasmid Midi Kit 12145 QIAgen (CA, USA) 
Precision Plus Protein™ Dual Color 
Standards  
#161-0374 Bio Rad (CA, USA) 
Gene Ruler 1 kb DNA Ladder #SM0311 
Thermo Scientific Inc. (IL, 
USA) 
Gene Ruler 100 bp DNA Ladder # SM0241 
Thermo Scientific Inc. (IL, 
USA) 
Kanamycin 60615 
Sigma Aldrich (St. Louis, 
USA) 
Carbenicillin  C1613 
Sigma Aldrich (St. Louis, 
USA) 
β-Galactosidase G5635 
Sigma Aldrich (St. Louis, 
USA) 
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Table 2.1.1 2: List of constructs and vectors 
Name  
pcDNA2.1 
3.9 kbp vector which bisulphite pcr 
products were cloned in it with TA cloning 
procedure.  
pcDNA.6TR 6662 bp vector coding tet repressor gene 
pcDNA 4/TO/ lacZ  
8224  bp control vector containing the 
gene for β-galactosidase under the control 
of tet repressor 
pcDNA3.1/His/lacZ 
Control vector constitutively expressing 
the gene for β-galactosidase to calculate 
transfection efficiency 
pcDNA 4/TO/ ALAS2 ALAS2 expressing expression vector 
pcDNA 4/TO/ CDR1 CDR1 expressing expression vector 
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Table 2.1.1 3: List of positive and negative controls 
Name Catalog number Company 
Human non-methylated DNA 
HCT116 DKO cells [DNMT1 (-/-) / 
DNMT3b (-/-) 
D5014-1 Zymo Research (CA, USA) 
Human methylated DNA 
SssI methylated  
HCT116 DKO cells [DNMT1 (-/-) / 
DNMT3b (-/-) 
D5014-2 Zymo Research (CA, USA) 
Human Normal Adult Colon Male 
DNA  
D1234090 (Lot 
no: A805046) 
BioChain (CA, USA) 
Human Normal Adult Colon Female 
DNA 
 BioChain (CA, USA) 
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Table 2.1.1 4: Primers used 
Primer Sequence Product 
Length 
Tm 
RT-PCR & Q-RT-PCR 
GAPDH F 5’-TTCTTTTGCGTCGCCAGCCG -3’ 78 
 
61.4 
GAPDH R 5’-CGACCAAATCCGTTGACTCCGACC -3’ 66.1 
TAGLN F 5’-ACGGCGGCAGCCCTTTAAACC -3’ 122 
 
60.24 
TAGLN R 5’-GGCCATGTCTGGGGAAAGAAGGC -3’ 59.74 
FN1 F 5’-TGTGATCCCGTCGACCAATGCC -3’ 131 
 
59.23 
FN1 R 5’-TGCCACTCCCCAATGCCACG -3’ 59.62 
VIM F 5’-CCAAGACACTATTGGCCGCCTGC -3’ 167 
 
60.36 
VIM R 5’-GCAGAGAAATCCTGCTCTCCTCGC -3’ 59.42 
CDX2 F 5’-CGCTTCTGGGCTGCTGCAAACG -3’ 262 
 
61.65 
CDX2 R 5’-TAGCTCGGCTTTCCTCCGGATGG -3’ 60.11 
CLDN4 F 5’- ACCTGTCCCCGAGAGAGAGTGC- 3' 157 
 
59.4 
CLDN4 R 5’ -GATTCCAAGCGCTGGGGACGG - 3' 60.11 
CDH1 F 5’ - TGGGCCAGGAAATCACATCCTACA - 3' 91 
 
57.57 
CDH1 R 5’- TTGGCAGTGTCTCTCCAAATCCGA - 3' 57.8 
TET1 F 5’- ACCTGCAGCTGTCTTGATCG- 3’ 186 60.39 
TET1 R 5’- ACACCCATGAGAGCTTTTCCC- 3’ 60.27 
TET2 F 5’- CGCTGAGTGATGAGAACAGACG- 3’ 
 
187 61.29 
TET2 R 5’- GCTGAATGTTTGCCAGCCTCG- 3’ 62.72 
TET3 F 5’- GCATGTACTTCAACGGCTGC- 3’ 187 60.18 
TET3 R 5’- ATTTCCTCGTTGGTCACCTGG- 3’ 60.27 
IκBG F 5’- AGCACAGCGTGCAGGTGGAC- 3’ 209 66.55 
IκBG R 5’- GAGATCTTCCAGCTGCATTCC- 3’ 62.57 
NY-ESO-1 F 5’- CAGGGCTGAATGGATGCTGCAGA- 3’ 365 66.33 
NY-ESO-1 R 5’- GCGCCTCTGCCCTGAGGGAGG- 3’ 72.33 
Noncoding RNA1 F 5’- CACTGGCCCCAATTAGGAAGAAC- 3’ 275 64.55 
Noncoding RNA1 R 5’- GAAGGCCTCATATCCCAATTCTAGC- 3’ 64.58 
Noncoding RNA2 F 5’- TGCATACCCTTCCAGCTGTAGG- 3’ 387 64.54 
Noncoding RNA2 R 5’- GGAGAAACCTTGGACAATACCCG- 3’ 64.55 
Noncoding RNA3 F 5’- GTTAAATTAGAGCGCATTCATATTGCG- 3’ 176 61.57 
Noncoding RNA3 R 5’- CTCACCCACTGCAAACATTCAATG- 3’ 62.86 
BISULPHITE SEQUENCING 
PAGE-2 1A 5’- TGGTGGTTTATTTTATAGAGGTAGG  -3’ 342 50.1 
PAGE-2 1B 5’- ACCCTTTTCCCTCAAAAACCA  -3’ 51.87 
PAGE-2 2A 5’- TGTTGGTGTTTATGTTTGTTGTTAT  -3’ 216 57.58 
PAGE-2 2B 5’- ACCAACTAACTCCTCCACACATT  -3’ 58.96 
PAGE-2B 1A 5’- TGGAAGTGAAAGAAAGGGTGGG - 3’ 398 54.44 
PAGE-2B 1B 5’- CAAAACCTATCCAAAACCAACTAACTC  -3’ 53.2 
PAGE-2B 2A 5’-  TTGTTGTTGTATTTGTTTGTTGTTA -3’ 238 56.55 
PAGE-2B 2B 5’- CTATCCAAAACCAACTAACTCCTC -3’ 57.33 
SPANX-B 1A 5’- TGGGTTGAAATTTGTTTGGTAGTAGTT  -3’ 523 53.81 
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SPANX-B 1B 5’- ACCCTCCCTATACATACCCTCC -3’ 53.50 
SPANX-B 2A 5’- ATTGTAGGAGGGAAATG-3’ 432 52.54 
SPANX-B 2B 5’- AAAACAAAACCACACCCT  -3’ 57.39 
ALAS2 1
st
 region 1A 5’- AGATTATATTGTTTTATAAAAAGGTGAG-3’ 395 51.5 
ALAS2 1
st
 region 1B 5’- CAACTTACTAACAAAAATCTAAAACC-3’ 51.8 
ALAS2 1
st
 region 2A 5’- TTTTTAAAGGAGAGGAGATATTAGG-3’ 273 55.4 
ALAS2 1
st
 region 2B 5’- CTATTACATTCAAATACATTTCC-3’ 54.5 
ALAS2 2
nd
 region 1A 5’- GGGTTTTATTTTTAGTAAGGAAGG-3’ 225 54.6 
ALAS2 2
nd
 region 1B 5’- CCTAAAAAACCAACTAACAAACC-3’ 56.1 
ALAS2 2
nd
 region 2A 5’- GATATTTTTGGGGTTAATGTAGG-3’ 152 56 
ALAS2 2
nd
 region 2B 5’- AAAACAACTCTTACCTATTACCC-3’ 55.5 
ALAS2 3
rd
  region 1A 5’- ATGTATTAGTTTTTTGATTTAGATAGG-3’ 244 51.1 
ALAS2 3
rd
 region 1B 5’- AATTCTTATCCCAATCCTATTAC-3’ 52.7 
ALAS2 3
rd
 region 2A 5’-TTTTATTATTATAGGGTTGATATGAG-3’ 156 51.1 
ALAS2 3
rd
 region 2B 5’- TAAACTTAAACTCTATAATTCCC-3’ 52.7 
CDR1 1
st
 region 1A 5’- TGGTTTTTTAGATTAGTATGTTGG-3’ 341 52.5 
CDR1 1
st
 region 1B  5’- AAATAAATACAAACACTTTCTAATACC-3’ 50 
CDR1 1
st
 region 2A 5’- ATTTAAGGAGTTGTAGTTATTATTAG-3’ 234 51 
CDR1 1
st
 region 2B  5’- CTTCAAAATCATATTCATAACTCC-3’ 50.7 
CDR1 2
nd
 region 1A 5’- TTTAAGGGAATGGTAGTAGTTGG-3’ 343 52 
CDR1 2
nd
 region 1B  5’- CCATTAAAACTAAATACCATCATTATCC-3’ 51 
CDR1 2
nd 
 region 2A 5’- AAATAGATTTTGGTAGTGATAGG-3’ 203 52.2 
CDR1 2
nd
 region 2B  5’- CTAAATAATAAAACCAAATTTAAACCC-3’ 50.4 
CDR1 3
rd
 region 1A 5’- GGATTATAGAATATGTTAGAATATTTGG-3’ 245 50.5 
CDR1 3
rd
 region 1B  5’- ATCTTCCTATATCTCCAAATCTTCC-3’ 51.9 
CDR1 3
rd 
 region 2A 5’- GAATGTTAGAAGATTAGTATATTGGAG-3’ 166 50 
CDR1 3
rd
 region 2B  5’- ATCTCCAAAACTTCCAACATCTAC-3’ 52.6 
hMEDIP-Q PCR 
PAGE-2 Primer #1 F 5’- GACTCAGCCGGTAGGTCTGC-3’ 
152 
62.3 
PAGE-2 Primer #1 R 5’- CTGGGAGGAGCTGGATGACG-3’ 62.0 
PAGE-2 Primer #2 F 5’- GAGCGCTGGTGGTTTACTCC-3’ 
173 
61.0 
PAGE-2 Primer #2 R 5’- TCCTTGCAGACCTCTGTGCG-3’ 62.4 
PAGE-2B Primer #1 F 5’- AGTCACGAGGCGAATGTCCC-3’ 
214 
62.2 
PAGE-2B Primer #1 R 5’- GACCTACCGGCTGAGTCTCG-3’ 61.7 
PAGE-2B Primer #2 F 5’- AGGTTCTCCACAGACGCAGG-3’ 
166 
61.8 
PAGE-2B Primer #2 R 5’- TGTGTGTGGACAGAAGGCGG-3’ 62.6 
SPANX-B Primer#1 F 5’- AACCTACTGTAGACATCGAAGAACC-3’ 
125 
60.1 
SPANX-B Primer#1 R 5’- CGTCTTGTTGGCCTCATTGGC-3’ 62.4 
ALAS2 Primer#1 F 5’- GAACACGGCCTGGCACA-3’ 
229 
60.26 
ALAS2 Primer#1 R 5’- ATGAACGTACAGCCAAGGG-3’ 57.45 
CDR1 Primer#1 F 5’- TGCTGGAAGACCTGGAGATA-3’ 
330 
57.45 
CDR1 Primer#1 R 5’- CCCTCAAATCCATAGCTTCCG-3’ 58.5 
PLASMID CONSTRUCTION 
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ALAS2 Primer #1 F 
(((BAmHI 
5'-ATTATTGGATCCACTTTAGGTTCAAGATGGTGACTGC- 3'  
1650 
62.
5 ALAS2 Primer #1 R  5'-ATTATTGCGGCCGCTGGCTTCTCAGGCATAGGTGG- 3'  65.
5 CDR1 Primer #2 F 5'-ATTATTGGATCCTGGAAGACATGGCTTGGTTGG- 3'  830 
62.
4 CDR1 Primer #2 R 5'-ATTATTGCGGCCGCTGGCTTCTCAGGCATAGGTGG- 3'  65.
5 SEQUENCING OF pcDNA2.1 
M13 reverse primer 5'- CAGGAAACAGCTATGAC -3'  51.
9  
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Table 2.1.1 5: List of antibodies used in IF staining and western blotting 
Name of the antibody Supplier Catalog number 
PRIMARY ANTIBODY 
Anti-fibronectin antibody Abcam (UK) ab23750 
Anti-vimentin antibody (EPR3776) Abcam (UK) ab92547 
Anti-transgelin (SM22 alpha) antibody Abcam (UK) ab14106 
Anti-CDX2 antibody (AMT28) Abcam (UK) ab15258 
Anti-PAGE-2,-2B antibody (C-13) 
Santa Cruz 
Biotechnology 
(Texas, USA) 
sc-168892 
Anti-SPANX-B antibody (N-13) 
Santa Cruz 
Biotechnology 
(Texas, USA) 
sc-162267 
Anti-TET2 antibody Abcam (UK) ab-94580 
Anti-TET2 antibody Active motif 61389 
SECONDARY ANTIBODY 
Alexa Fluor 488 donkey anti-goat IgG 
(H+L) 
Invitrogen by Life 
Sciences(CA, USA) 
A11055 
Alexa Fluor 568 donkey anti-rabbit IgG 
(H+L) 
Invitrogen by Life 
Sciences(CA, USA) 
A10042 
Alexa Fluor 568 donkey anti-mouse IgG 
(H+L) 
Invitrogen by Life 
Sciences(CA, USA) 
A10037 
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Table 2.1.1 6: List of antibodies used in ChIP 
Name of the antibody Supplier Catalog number 
PRIMARY ANTIBODY 
Anti-EZH2 Abcam (UK) ab3748 
Anti-HP1 Abcam (UK) ab77256 
Anti-H3K27me3 Abcam (UK) ab6002 
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2.1.2 Instruments 
Table 2.1.2 1: List of instrument 
Name Company 
Applied Biosystem 7500 Q RT PCR 
Machine 
Applied Biosystems by Life Sciences (CA, 
USA) 
Applied Biosystem PCR Machine 
Applied Biosystems by Life Sciences (CA, 
USA) 
AutoFlow NU-8500 Water Jacket CO2 
Incubator 
NuAire (MN, USA) 
The STANDARD CO2 incubator Binder (Tuttlingen, GERMANY) 
Centrifuges 5810 and 5810 R Eppendorf (Hamburg, GERMAY) 
Electrophoresis Equipment  
XCell SureLock™ Mini-Cell 
Electrophoresis System 
Life Sciences (CA, USA) 
AxioCam MRc5 image capture device Carl Zeiss (Oberkochen, GERMANY). 
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2.1.3 Cell Lines and Tissue Culture Reagents 
The Caco-2 cell line was obtained from the SAP Enstitusu (Ankara, Turkey). 
HCT116, SW620, LoVo (colorectal cancer), MDAMB-157, MCF-7 (breast cancer) and 
Mahlavu (hepatocellular cancer) cancer cell lines were obtained from LGC Standards 
(Middlesex, UK). A lung cancer cell line, SK-LC-17, was from the Memorial Sloan 
Kettering Cancer Center (NY, USA).  
Plastic cell culture materials such as; petri dishes, T-75 and T-25 cm flasks, 
multi-well plates, cryotubes were purchased from Greiner Bio-One (Austria) and 
serological pipettes were purchased from Costar Corporation (Cambridge, England). 
Other materials were listed below.  
Table 2.1.3 1: List of cell culture reagents 
Name Catalog number Company 
RPMI 1640 medium F 1215 
Biochrom AG )Berlin, 
Germany) 
DMEM medium FG 0415 
Biochrom AG  (Berlin, 
Germany) 
EMEM medium BE12-125F  Lonza (USA) 
Trypsin-EDTA SV3003101 HyClone (IL, USA) 
L-Glutamine SH3003401 HyClone (IL, USA) 
Penicillin/Streptomycin SV30010 HyClone (IL, USA) 
Non-essential amino acids SH3023801 HyClone (IL, USA) 
Fetal Bovine Serum S1620  
Biowest (Nuaille, 
FRANCE) 
Blasticidin S HCl A11139-02 
Invitrogen by Life 
Sciences(CA, USA)  
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Zeocin Selection reagent R25001 
Invitrogen by Life 
Sciences(CA, USA)  
Opti-MEM® I Reduced 
Serum Medium 
31985-062 
Invitrogen by Life 
Sciences(CA, USA)  
Tetracycline 87128 
Sigma Aldrich (St. Louis, 
USA) 
Tetracycline reduced Fetal 
Bovine Serum  
631106 Clontech (CA,USA) 
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2.2 SOLUTIONS AND MEDIA  
2.2.1 General Solutions 
10X PBS 
 25.6 g Na2HPO4·7H2O 
 80 g NaCl 
 2 g KCl 
 2 g KH2PO4 
 Bring to 1 liter with H2O. 
Lysis Solution for DNA isolation (300 µl):  
 150 µl TE  
 Add 150 µl Proteinase K (from 200 µM stock)  
 15 µl SDS (from %10 SDS stock). 
LB (500 ml): 
 5 g Tryptone 
 5 g NaCl 
 2.5 g Yeast Extract in 500 ml ddH2O 
LB Agar + Carbenicillin (or Amphicillin)+ IPTG+ X-Gal (500 ml):  
 5 g Tryptone 
 5 g NaCl 
 2.5 g Yeast Extract 
 12.5 g Bacto Agar in 500 ml ddH2O 
 After autoclaving and cooling down the solution 
o Add carbenicillin to make it 1X (from 1000X add 500µl ) 
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o Add 250 µl IPTG from 1M stock (Final conc= 0.5 mM) 
o Add 1000 µl X-Gal from 40 mg/ml stock (Final conc= 80 µg/ml) 
o Pour the agar in plates 
SOC medium (100 ml):  
 2 g Tryptone 
 0.5 g Yeast extract 
 1000 µl 1M NaCl solution 
 250 µl 1M KCl solution 
 Add 97 ml ddH2O then autoclave 
 After autoclaving  
o Add 1000 µl 2M Mg+2 stock solution (1M MgCl2.6H2O and 1M 
MgSO4.7H2O) (previously filter sterilized) 
o Add 1000 µl 2M Glucose (previously filter sterilized) 
 
RIPA Buffer (5 ml):  
 750 µl NaCl from 1M stock (final concentration 150 mM) 
 50 µl Triton-X (final concentration 1%) 
 50 µl from 10% Sodium DOC (final concentration 0.5%) 
 25 µl from 20 %SDS (final concentration 0.1%) 
 250 µl from 1M Tris-HCl at pH:8.0 (final concentration 50mM) 
 Protease cocktail from 100X to 1X  
 ddH2O up to 5 ml 
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2.2.2 Cell Culture Solutions 
Complete DMEM and RPMI 
 10 % FBS  
 1 % L-Glutamine 
 1 % Penicillin/Streptomycin 
 500ml Medium 
Complete EMEM  
 20 % FBS  
 1 % L-Glutamine 
 1 % Penicillin/Streptomycin 
 1 % Non-essential amino acid solution 
 1 % Sodiumbicarbonate 
 1 % Sodiumpyruvate 
 500ml Medium 
Blasticidin 
 10mg/ml of stock Blasticidin solution was prepared in sterile water, aliquoted 
then stored at -20
0
C.  
Tetracycline 
 5 mg/ml stock solution of tetracycline was prepared in 70% ethanol 
Freezing mix 
 90% FBS 
 10% DMSO 
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2.3 METHODS 
 
2.3.1 Cancer cell culture techniques 
Human colorectal cancer cell lines; HCT116, SW620, LoVo and human small 
cell lung cancer cell line; SK-LC-17 were grown in RPMI medium supplemented with 
10% (v/v) heat-inactivated FBS, 1% L-glutamine and 1%penicillin/streptomycin.  MCF-
7 cells were grown in high glucose DMEM medium supplemented with 10% (v/v) heat-
inactivated FBS, 1% L-glutamine , 1%penicillin/streptomycin,  1% insulin, 1% sodium 
pyruvate and MDA-MB-157 cells were cultured in DMEM medium supplemented with 
10% (v/v) heat-inactivated FBS, 1% L-glutamine and 1%penicillin/streptomycin. 
HCT116.6TR and SK-LC-17.6TR clones were cultivated in complete RPMI medium 
containing 2 μg/ml and 1.2 μg/ml Blasticidin respectively. All cell lines were maintained 
in a 5 % CO2 atmosphere at 37
0
C.   
All cells were cultured by renewing the medium for every 2-3 days. When cells 
reached confluency, they were washed 1X PBS then harvested with trypsin-EDTA 
incubation and reseeded with complete medium. Stocks were prepared with   90% 
DMSO and 10% FBS containing freezing mix by freezing at -20 and -80 
0
C 
respectively. Then stocks were maintained at liquid nitrogen.  
 
2.3.2 RNA isolation with TRIzol 
 One confluent T-75 flask of cells was used for RNA isolation. Cells were washed 
with 1X PBS, and then scraped with 1X PBS. After centrifugation, supernatant was 
removed and 1ml TRIzol was added. Cells were pipetted and homogenized in TRIzol by 
5 minutes incubation at room temperature. 200 µl of chloroform was added. The mixture 
was mixed vigorously, incubated at 10 minutes at room temperature then centrifuged at 
13000 rpm 15 minutes at 4 
0
C. Upper phase was removed, 500 µl isopropanol was 
added. The mixture was inverted gently and incubated at 10 minutes at room 
temperature then centrifuged at 13000 rpm 15 minutes 4 
0
C. The precipitate was washed 
with 75 % ethanol, ethanol was removed with centrifugation. The pellet was air dried 
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and then resuspended in nuclease free water. RNA was incubated at 55
0
C for 15 minutes 
to complete dissolution. RNAs were stored at -80 
0
C for longer storage.  
 
2.3.3 DNA Isolation with Phenol-Chloroform-Isoamylalcohol Extraction 
One confluent T-75 flask of cells was used for DNA isolation. Cells were 
washed with 1X PBS, and then scraped with 1X PBS. After centrifugation, supernatant 
was removed and pellet was dissolved in 300 µl lysis buffer by pipetting up and down. 
The mixture was incubated at 50
0
C for overnight.  300 µl phenol-chloroform-isoamyl 
alcohol was added, mixture was vortexed and centrifuged at 5000 rpm 10 minutes at 
room temperature. The upper phase was removed, 250 µl phenol-chloroform-isoamyl 
alcohol was added, mixture was vortexed and centrifuged at 5000 rpm 10 minutes at 
room temperature. Upper phase was removed, 200 µl chloroform was added, mixture 
was vortexed and centrifuged at 5000 rpm 10 minutes at room temperature. The upper 
phase was transferred into a new tube, 50 µl 3 M NaOAC then 375 µl % 100 ice cold 
EtOH were added onto it. The mixture was inverted gently until the precipitate appeared. 
The precipitate was removed by a pipette tip and transferred to a tube containing 70% 
ethanol. Then the mixture was centrifuged at 13000 rpm 3 minutes at room temperature. 
Supernatant was removed, the pellet was air dried and resuspended in nuclease free 
water. To dissolve DNA, DNA was incubated at 65
0
C for 2 hours then stored at -20
0
C.  
 
2.3.4 Identification of CT-proximal down-regulated genes in cancer compared to 
healthy counterparts by Cancer Genome Anatomy Project 
X-chromosome genes that were downregulated, with respect to their normal 
counterparts, in any human cancerous tissues except from embryonic and germ line 
origin were identified by analyzing SAGE Digital Gene Expression Displayer and 
cDNA Digital Gene Expression Displayer databases of the Cancer Genome. Anatomy 
Project based on SAGE and EST libraries. Among existing EST libraries, 269 libraries 
of cancerous tissues versus 339 libraries of healthy tissues were screened. Among 
existing SAGE libraries, 78 libraries of cancerous tissues versus 182 libraries of healthy 
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tissues were screened. Significance filter was adjusted to p<0.05. 59 genes were 
obtained based on the above criteria. Extracted data were checked by using 
Monochromatic SAGE/cDNA Virtual Northern. Among the 59 genes, 8 genes that have 
a neighboring cancer-testis (CT) gene were chosen and expression analyses were made 
to verify the database data. These 8 genes were located at least 30kb and at most 560kb 
from a CT gene.  
 
2.3.5 Q RT-PCR Experiments with Taqman Probe Chemistry 
Nuclear and cytoplasmic RNA species were prepared with guanidium 
thiocyanate phenol-chloroform extraction method using TRIzol reagent. 500 ng of RNA 
was reverse transcribed using Revert-Aid first strand cDNA synthesis kit from 
Fermentas with random hexamer primer and RNase inhibitor. All PCR reactions were 
carried out in triplicates in ABI 7500 RT-PCR machine by using Taqman predesigned 
probes and Taqman gene expression mix of Applied Biosystems. The assay IDs of 
probes used in the experiments were: Hs00163601_m1* for ALAS2, Hs00601346_s1* 
for CDR1, 4352934E for GAPDH, Hs02387419_gH for SPANX-B family genes and 
Hs03805505_mH for PAGE-2 and PAGE-2B genes. Thermal cycle conditions were as 
follows:  50
0
C for 2 min, 95
0
C for 10 min followed by 45 cycles of 94
0
C for 15 sec, 
60
0
C for 1 min.   
 
2.3.6 Sequencing of sodium bisulphite treated tumor cell lines’ and normal tissues’ 
DNAs  
Genomic DNAs from cell lines were isolated by Proteinase K treatment, 
following phenol-chloroform extraction protocol. Control human female and male 
genomic colon DNAs were purchased from Biochain. Human HCT116 DNMT1 (-/-) & 
DNMT3b (-/-) double knockout cell  line DNA and Human HCT116 DNMT1 (-/-) & 
DNMT3b (-/-) double knockout cell line SssI treated DNA were used as non-methylated 
and methylated DNA controls and were purchased from Zymo Research. Bisulphite 
treatment of 200 ng genomic DNA was performed with Zymo DNA Methylation Gold 
Kit according to the instructions. The bisulphite modified DNA was stored at -20
0
C and 
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used for PCR up to 2 months. For PCR amplification, 1 μl of DNA was added in a final 
volume of 20 μl, containing 1X PCR buffer, dNTP (200 μM final concentration), 
primers (final concentration 0.5 μM of each) and 0.03 unit/ μl of DyNAzyme II Hot 
Start DNA polymerase. PCR product was 1: 10 diluted and 1 μl of this dilution was used 
in nested PCR reaction with primers designed specific to initial PCR product. The 
primers were designed to recognize bisulphite converted DNA only. PCR reactions were 
carried out in a Perkin Elmer cycler using the following protocol: 94
0
C for 10 min, 35 
cycles of 94
0
C for 15 sec, 55
0
C for 30 sec, and 72
0
C for 30 sec, followed by a final 
extension at 72
0
C for 10 min and soaking at 4
0
C. After electrophoresis on 1.5 % agarose 
gel, products were gel extracted with QIAgen gel extraction kit and cloned in pCR2.1 
linearized vector using TA cloning kit Invitrogen. Clones were picked according to blue-
white colony screening. Plasmid DNA from white colony was EcoRI digested to release 
the insert as a further confirmation. Plasmid DNAs from at least ten clones were picked 
and sequenced by IONTEK, Istanbul.    
Ligation reaction was performed such as:  
PCR product (10ng)       … µl 
10X Ligation Buffer…..   1 µl 
pCR 2.1 vector………      1 µl 
ddH2O………………    … µl 
T4 DNA Ligase………    1 µl 
Final volume………      10 µl 
2.3.7 Plasmid constructions 
PCR for cloning experiment was carried out under the conditions of 98
0
C for 30 
sec followed by 40 cycles of 98
0
C for 30 sec, appropriate melting temperature (68
0
C for 
ALAS2 and 72
0
C for CDR1) for 30 sec, 72
0
C for 1 min with a final extension at 72
0
C 
for 10 min in Perkin Elmer PCR machine. For ALAS2 placenta cDNA and for CDR1 
brain cDNA were used in the PCR. Phusion High Fidelity DNA polymerase,  5X GC 
Buffer, dNTP mix, forward and reverse primers at final concentrations of 0.02 unit/μl 
,1X, 200 μM ,0.5 μM of each respectively were used. PCR products at correct band size 
were run on % 1.5 agarose gel at 100V for 40 minutes and then gel extracted. For 
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ALAS2 BamHI and NotI double digestion, for CDR1 XbaI and HindIII double digestion 
were performed. pcDNA 4/TO vector was also double digested with ether BamHI and 
NotI or XbaI and HindIII. All of the digested products were purified from enzymes and 
buffers with gel extraction and digested inserts were ligated with cut pcDNA 4/TO. 
After ligation and transformation, colonies having the vector were selected with 
amphicillin resistance and plasmid DNA purification was performed with QlAprep Spin 
Miniprep kit. Plasmid DNA was cut with appropriate digestion enzymes and clones 
having the appropriate insert were grown for plasmid DNA purification and plasmid 
DNA was sent to sequencing with CMV forward and BGH reverse primers.     
Both pcDNA6/TR and insert containing pcDNA4/TO plasmid DNAs were transformed 
in DH5α Ecoli strain and plasmid DNAs for transfection experiments were prepared 
with QIAGEN Plasmid MidiPrep Kit.    
 
2.3.8 Generation of stable cell lines 
Before stable transfection with pcDNA.6TR vector, 7x10
4
 untransfected 
HCT116 and SK-LC-17 were plated on six-well culture dishes. The next day, culture 
medium was substituted with medium containing Blasticidin at different concentrations 
(0.5, 1, 1.5, 2, 2.5 and 3 μg/ml for HCT116; 1, 1.2, 1.4, 1.6, and 1.8 μg/ml for SK-LC-
17). The selective medium was replenished for every 3 days and the Blasticidin dose 
leading to cell death within 10-14 days after the addition of antibiotic was chosen as the 
selection dose in pcDNA6TR transfection experiments. 
For stable transfection 2x10
5 
HCT116 cells and 5x10
5
 SK-LC-17 cells were 
plated on six-well culture dishes and transfected after 48 hours with 4 μg of FspI cut 
pcDNA.6TR plasmid DNA using Lipofectamine in a 1:2 ratio in OPTI-MEM medium. 4 
hours later the transfection medium was removed and cells were cultured in complete 
RPMI medium for overnight. Next day, cells were splitted at 1:10, 1:5 and 1:2 ratios and 
Blasticidin at pre-determined concentration required each cell line was introduced into 
the medium 24 hours later. Cells were feeded with the selection medium every 3 days 
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for 14 days. Then, cells were plated in a 96-well plate by serial dilution to obtain single 
cell colonies. Colonies were picked during 2 weeks period and cultured.              
 
2.3.9 β-Galactosidase Staining Assay 
1.5x10
5 
HCT116.6TR cells and SK-LC-17.6TR cells were plated on twelve-well 
culture dishes and later 24 hours transfected with 1 μg of pcDNA.4TO/lacZ plasmid 
DNA using Mirus Trans-IT LT1 transfection reagent at a 1:3 ratio (DNA:Transfection 
reagent) in OPTI-MEM medium. 1 day later the transfection medium was removed and 
cells were cultured in complete RPMI medium (Prepared with tetracycline reduced FBS) 
containing either 1 μg/ml Tetracycline or not. pcDNA3.1/His/lacZ transfection was also 
performed as a positive control. 24 and 48 hours after tetracycline induction, transfected 
cells were fixed with fixation solution composed of formaldehyde and gluteraldehyde 
for 10 minutes at room temperature. After fixation, cells were stained with staining 
solution containing X-gal for 30 minutes to 2 hours. Stained cells were covered with 70 
% glycerol and images were taken at 50X, 100X and 200X total magnification. 
 
2.3.10 MTT Cell Viability Assay 
7.5x10
4
 HCT116.6TR_clone 4 and HCT116.6TR_clone 9, 1.0x10
4
 SK-LC-
17.6TR clone_5 cells were plated on 96-well plate without Blasticidin. 24 hours later, 
transfection was carried with mixing 1 µg plasmid DNA (pcDNA 4/TO-ALAS2-A3 and 
pcDNA 4/TO-ALAS2-A4) and 3 µl Mirus in 100 µl OPTI-MEM and pipetting 10µl of 
this mixture onto cells that were supplemented with 100 µl OPTI-MEM. After 24 hours 
incubation transfection medium was replaced with complete RPMI medium (Prepared 
with tetracycline reduced FBS) containing either 1 μg/ml Tetracycline or not. 48 hours 
after induction, viability was measured by MTT cell proliferation kit from Roche. 
Untransfected cells were accepted as 100 % alive in order to calculate percent viability.     
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2.3.11 Spontaneous differentiation and dedifferentiation of Caco-2 cell line 
Caco-2 cells (ŞAP Enstitüsü, Ankara, Turkey) were grown in EMEM 
supplemented with % 20FBS, 2mM L-glutamine, 0.1 mM non-essential amino acids, 1.5 
g.L
-1
 sodium bicarbonate and 1 mM sodium pyruvate. Cells were grown until 
confluency and the % 100confluent cells were considered to be at day 0 for 
differentiation. The cells were collected at various intervals (day 0, 10, 20 and 30) until 
day 30 after reaching confluency.  The differentiation monitored with sucrose isomaltose 
expression and alkaline phosphatase staining. Parallel cultures were carried on to obtain 
replicated differentiation sets. For the dedifferentiation, cells at day 20 were detached by 
typsinizing and pipetting  then reseeded  at  50 % confluency. Cells were cultured 
following  5 days for RNA and DNA isolation.  
 
2.3.12 In silico analysis of CT gene expression during Caco-2 spontaneous 
differentiation   
GSE1614 was a microarray experiment performed at 3 time points; day 2 (% 50 
confluent cells), day 8 (4 days post-confluent, non-differentiated cells) and day 15 
(differentiated cells) during Caco-2 cell line spontaneous differentiation by using 
Affymetrix Human Genome U95A GeneChip.  The raw data of GSE1614 was imported 
from GEO database and analyzed with GeneSpring GX11 software of Agilent 
technologies. The data was normalized with GC-RMA normalization method. 
Experimental grouping was done according to three time points in the experiment (2 
days, 8 days and 15 days). An interpretation was generated with entity list composed of 
CT genes and at three different time points. The list was not further processed with 
statistical analysis to have a general picture of CT gene expression during Caco-2 
differentiation.  
 
2.3.13 Total RNA isolation and DNaseI treatment 
Nuclear and cytoplasmic RNA species of Caco-2 cells were isolated with TRIzol 
reagent from different time points during spontaneous differentiation process. DNase I 
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treatment was performed with DNA free kit with incubation of RNAs at 37
0
C 30 
minutes with DNase I and 1X DNase I Buffer in 50µl solution. DNase I was further 
inactivated with inactivation buffer and RNAs were precipitated with ammonium 
acetate, linear acrylamide and ice cold ethanol. The precipitated RNAs were washed 
with 75% ethanol and resuspended in nuclease free water.    
 
2.3.14 cDNA synthesis 
200 ng of RNA was reverse transcribed using Revert-Aid first strand cDNA 
synthesis kit with random hexamer primer and RNase inhibitor. 
 
2.3.15 Q RT-PCR of CT genes 
All PCR reactions were carried out in triplicates in ABI 7500 RT-PCR machine. 
The assay IDs of ABI probes used in the experiments were: 4352934E for GAPDH, 
Hs02387419_gH for SPANX-B gene, Hs03805505_mH for PAGE-2 and PAGE-2B 
genes, Hs00275620_m1 for GAGE family genes, Hs023441531_m1 for SSX4,-4B 
genes, Hs00265824_m1 for NY-ESO-1 gene, Hs00366532_m1 for MAGEA3 gene 
.Thermal cycle conditions were as follows:  50
0
C for 2 min, 95
0
C for 10 min followed 
by 45 cycles of 94
0
C for 15 sec, 60
0
C for 1 min. The relative expression values were 
calculated with ΔΔCt method.    
 
2.3.16 In silico identification of differentially expressed mesenchymal and epithelial 
genes during Caco-2 spontaneous differentiation  
The raw data of GSE1614 was imported from GEO database and analyzed with 
GeneSpring GX11 software of Agilent technologies. The data was normalized with GC-
RMA normalization method. Experimental grouping was done according to three time 
points in the experiment (2 days, 8 days and 15 days). An interpretation was generated 
with entity list composed of EMT related gene list in colorectal cancer generated by 
Loboda et al and at three different time points. The list was further processed with 
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statistical analysis by using one way ANOVA test and Bonferroni FWER correction 
method. Genes having a p value smaller than 0.05 were ranked according to biggest 
expression value difference between day 2 and day 15 values.  
 
2.3.17 Q RT-PCR of mesenchymal and epithelial marker genes  
All PCR reactions were carried out in triplicates in ABI 7500 RT-PCR machine. 
2X SYBR Green master mix with ROX reference dye was used. Thermal cycle 
conditions were as follows:  50
0
C for 2 min, 95
0
C for 10 min followed by 40 cycles of 
94
0
C for 15 sec, 60-65 
0
C for 1 min. In all experiments, melt curve was also ran. The 
relative expression values were calculated with ΔΔCt method.    
 
2.3.18 Promoter methylation analysis 
Genomic DNA from Caco-2 cell line at different time points of differentiation 
was isolated by Proteinase K treatment, following phenol-chloroform extraction 
protocol. Bisulphite treatment of 200 ng genomic DNA was performed with Zymo DNA 
Methylation Gold Kit. The bisulphite modified DNA was stored at -20
0
C and used for 
PCR up to 2 months. For PCR amplification, 1 μl of DNA was added in a final volume 
of 25 μl, containing 1X PCR buffer, dNTP (200 μM final concentration), primers (final 
concentration 0.2 μM of each) and 0.025 unit/ μl of One Taq Hot Start DNA 
polymerase. PCR product was 1: 10 diluted and 1 μl of this dilution was used in another 
PCR reaction with primers designed specific to initial PCR product. The primers were 
designed to recognize bisulphite converted DNA only. PCR reactions were carried out in 
a Perkin Elmer cycler using the following protocol: 94
0
C for 30 sec., 35 cycles of 94
0
C 
for 15 sec, 55-58
0
C for 30 sec, and 68
0
C for 30-45 sec, followed by a final extension at 
68
0
C for 5 min and soak at 4
0
C. After gel electrophoresis on % 1.5 agarose gel, products 
were gel extracted with QIAgen gel extraction kit and cloned in pCR2.1 linearized 
vector using TA cloning kit. Clones were picked according to blue-white colony 
screening. Plasmid DNA from white colony was EcoRI digested to release the insert as a 
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further confirmation. Plasmid DNAs from at least ten clones were picked and sequenced 
by IONTEK, Istanbul.    
 
2.3.19 Hydroxymethylated DNA Immunoprecipitation 
gDNAs of the cell lines were sheared by probe by sonication (30 sec on, 30 sec 
off 5 cycles) to obtain 200-600 bp fragments. The size of the fragmented DNA was 
controlled by % 1agarose gel electrophoresis analysis. Immunoprecipitation was carried 
out by hMEDIP kit according to the instructions. 5 pg of control DNA was spiked into 
500 ng of gDNA to use as an internal control. Positive and negative controls of the kit 
were also included in all experiments. 2 µl from the eluted DNA was used as template in 
Q RT-PCR. The efficiencies of primers were controlled. 2 X SYBR Green master mix 
with ROX reference dye was used. Thermal cycle conditions were as follows:  50
0
C for 
2 min, 95
0
C for 10 min followed by 40 cycles of 94
0
C for 15 sec, 60 
0
C for 1 min. In 
order to calculate with input % method, unsheared gDNA were included in Q RT-PCR 
and the calculations were done with input % method.  
 
2.3.20 Immunofluorescence microscopy 
Caco-2 cells at different time points during differentiation were scraped with 
PBS and attached to the lam by cytospin instrument (800 rpm for 3 min). The attached 
cells were immediately fixed with 2%formaldehyde in PBS incubation at room 
temperature for 15 min. Fixed cells were further permeabilized with 0.2%Triton X-PBS 
for 10 min. The blocking was performed with 1% BSA mixture in 0.1%PBS-Tween for 
1 hour. The primary antibody incubations were performed 1:50 dilution for overnight at 
4
0
C. The secondary antibody incubations were performed at 1:200 dilution for 45 
minutes at room temperature. Washing steps were done with 0.1%PBS-Tween for 5 
minutes and 3 times. Slides were finally closed with Santa Cruz Mounting medium 
containing DAPI solution. Proper positive controls (For PAGE-2,-2B and SPANX-B; 
Mahlavu cell lines, for VIM; MDA-MB 231 cell line, for TAGLN MCF-7 cell line, for 
CDX2 and FB1 SW620 cell line) and negative controls (Primary antibody#1+Secondary 
40 
 
antibody#2,  Primary antibody#2+Secondary antibody#1, Secondary antibody #1 and 
#2) were also included in the experiments.  Images were taken at fixed instrument 
settings.     
 
2.3.21 Protein Isolation 
The pelleted cells (stored at -80°C) were resuspended in 200-300 µl RIPA 
depending on the amount of pellet. Then the sample was incubated on ice for 30 min. 
with vortexing every 5 min. The sample was sonicated for 5 sec for 4 rounds then 
incubated on ice for 5 min. The sample was boiled at 90°Cfor 3 min and centrifuged at 
14000rpm for 75 min. +4°C. Finally supernatant was taken and stored at -80 
0
C. 
 
2.3.22 Western Blotting 
 Isolated proteins were run on 4-12%Novex Bis-Tris SDS gels at 120 V for 2 
hours. Gels were transferred to PVDF membrane with the wet transfer at 30 V for 2 
hours. Blots were blocked with 5% milk powder in 0.02% PBS-T. The primary antibody 
incubations were performed at the indicated dilutions; 1:1000 for CDX2, fibronectin, 
vimentin and transgelin, 1:2500 for β-actin, 1:100 for SPANX-B and PAGE-2,-2B 
antibodies, for overnight at 4
0
C. Secondary antibody incubations were performed at 
dilution ratio 1:5000 at room temperature for 1 hour with the suitable HRP conjugated 
secondary antibodies. The detection was performed with ECL based method.   
 
2.3.23 Chromatin Immunoprecipitation (ChIP) 
Caco-2 cells were grown in 10cm dishes. On the 0th, 10th and 20th days after 
reaching 100% confluency, the culture medium was refreshed and 0.8% formaldehyde 
was added to initiate the crosslinking, incubated at room temperature for 7 min and 
stopped by adding glycine to a final concentration of 125mM. Cells were washed with 
PBS twice, scraped into 1.5ml eppendorf tubes and centrifuged at 13000 x g for 1min at 
4°C. The pellets were then frozen in liquid nitrogen and then thawed in buffer A (200M 
HEPES-KOH pH7.5, 420mM NaCl, 0.2mM EDTA ph8.0, 1.5mM MgCl2, 25%glycerol, 
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1X protease inhibitor). Thawed cells were incubated on ice for 20 min and centrifuged 
after which they were resuspended in breaking buffer (50mM Tris-Cl pH8.0, 1mM 
EDTA pH8.0, 150mM NaCl, 1% SDS, 2% Triton X-100, 1X protease inhibitor) and 
sonicated with a probe sonicator for 12 cycles in 30sec intervals of sonication and 
incubation on ice. Then, 50 µl inputs were taken and subjected to de-crosslinking (1hr 
RNaseA at 37°C, 1hr Proteinase K at 50°C and o/n incubation at 60°C) in buffer C 
(50mM Tris-Cl pH8.0, 1mM EDTA pH8.0, 150mM NaCl, 0.1% Triton X-100). The 
inputs were ran on 1% agarose gel to confirm the size of the sonicated fragments (200-
1000 bp) and DNA amount was measured. The samples in buffer B were seperated so 
that each contained 25µg DNA and were centrifuged at 13000 rpm for 10 min. The 
pellets were resuspended in Buffer C and 2µg of antibody or isotype specific control IgG 
was added incubated at 4°C with constant agitation o/n. The samples were then 
incubated with pre-blocked proteinA/G agarose beads for 2hr at 4°C with constant 
agitation and washed three times with wash buffer 1 (0.1% SDS, 1%Triton X-100, 2mM 
EDTA pH8.0, 150mM NaCl, 20mM Tris-Cl pH8.0) and then with wash buffer 2 (0.1% 
SDS, 1%Triton X-100, 2mM EDTA pH8.0, 500mM NaCl, 20mM Tris-Cl pH8.0). 
Samples were then eluted with elution buffer (1% SDS, 100mM NaHCO3) and subjected 
to de-crosslinking as mentioned before. DNA were isolated with high pure PCR product 
purification kit. Q-PCR was carried out with both immunoprecipitated and input samples 
using hMEDIP primers designed for the CpG regions of promoters of PAGE-2, PAGE-
2B and SPANX-B. The analyzes were performed by normalizing the Ct values to their 
isotype IgG values. 
 
2.3.24 In vitro treatment of tumor cell lines with 5-aza-2-deoxycytidine  
5x10
5
 HCT116, 10x10
5
 SK-LC-17, LoVo, SW620, HT29, Colo205, WiDR, 
MCF7, CAMA-1 cells were seeded in 100mm cell culture dishes. 24 hours later, the 
medium was renewed with 1 μM 5-Aza-2-deoxycytidine containing medium. RNAs 
from 5-Aza-2-deoxycytidine treated cells and DMSO treated control cells were isolated 
at 24 hours, 48 hours and 72 hours’ time points.  
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2.3.23 Q RT-PCR Experiments with SYBR Green chemistry for noncoding RNA 
expression in NY-ESO-1 repeat region  
Nuclear and cytoplasmic RNA species were prepared with guanidium 
thiocyanate phenol-chloroform extraction method using TRI-reagent. To eliminate 
genomic DNA contamination, all samples were treated with RNAase and DNA free 
DNAse. 500 ng of RNA was reverse transcribed using Revert-Aid first strand cDNA 
synthesis kit from Fermentas with random hexamer primer and RNase inhibitor. All 
PCR reactions were carried out in triplicates in ABI 7500 RT-PCR machine. 2X SYBR 
Green master mix with ROX reference dye from Applied Biosystem was used. Thermal 
cycle conditions were as follows:  50
0
C for 2 min, 95
0
C for 10 min followed by 40 
cycles of 94
0
C for 15 sec,  61 
0
C for 30 sec, 72 
0
C for 45 sec and 72 
0
C for 10 min for 
final extension. In all experiments, melt curve was ran.    
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3 RESULTS: 
3.1 EPIGENETIC MECHANISMS LEADING CANCER TESTIS GENE 
EXPRESSION IN CACO-2 SPONTANEOUS DIFFERENTIATION 
MODEL 
3.1.1 Cancer Testis gene expression in Caco-2 spontaneous differentiation model: 
To investigate whether Caco-2 spontaneous differentiation was a suitable model 
to study CT gene expression, we used a microarray study performed by Fleet et al. 
(GSE1614) [64]. When we searched for various CT genes annotated in the U95A 
platform, we observed that many CT genes were up-regulated in the differentiation 
process from 2 to 15 days (Error! Reference source not found.). We, therefore, 
decided to validate this data in vitro.  
 
Figure 3.1.1 1: CT gene expression increases during Caco-2 spontaneous 
differentiation. 
Heat map of CT-X gene expression in Caco-2 spontaneous differentiation generated 
from GSE1614 dataset. Experimental grouping was done according to three time points 
in the experiment (2 days, 8 days and 15 days). An interpretation was generated with 
entity list composed of CT genes and at three different time points.   
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Caco-2 spontaneous differentiation model is a well-established enterocytic 
differentiation model. Functional and absorptive intestinal epithelial cells developed 
from Caco-2 colon adenocarcinoma cell line upon contact inhibition after confluency 
[39,65]. Increase in sucrose isomaltose mRNA level, alkaline phosphatase staining and 
carcinoembryonic antigen protein level showed that differentiation had taken place 
successfully in our experimental set up.  
 
Figure 3.1.1 2: Caco-2 cells differentiate during 30 days post confluence culturing. 
Caco-2 cells differentiated upon 30 days post confluence culture. (A) Differentiation 
was confirmed with the increase in mRNA level of sucrose isomaltase expression and 
(B) protein level of carcinoembryonic antigen. (C) The up-regulation in alkaline 
phosphatase level was also showed with immnuhistochemistry. The difference in 
sucrose isomaltase expression was statistically significant with ANOVA with Tukey’s 
post hoc test (*P< 0.001). (These experiments were performed by Dr. Aslı Sade 
Memişoğlu from METU)  
 
When we analyzed CT gene expression in the Caco-2 spontaneous differentiation 
model, we observed that 3 CT genes; PAGE-2, PAGE-2B and SPANX-B were up-
regulated dramatically. We were unable to observe a change in gene expression for 
MAGE-A3, NY-ESO-1, SSX4 and GAGE family genes. Up-regulation of PAGE-2,-2B 
and SPANX-B genes was further confirmed at 4 different time points in two different 
differentiation experiments.  
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Figure 3.1.1 3: Among 6 CT gene families; the gene expressions of PAGE-2,-2B and 
SPANX-B increase in Caco-2 spontaneous differentiation. 
The relative mRNA expressions of various CT genes were shown during Caco-2 
spontaneous differentiation at 3 different time points by Taqman probe q RT-PCR. 
GAPDH gene was used as endogenous control. Mahlavu cell line RNA was used as 
reference sample in ΔΔCt calculations due to the well-known CT gene expression levels.  
 
3.1.2 Characterization of Caco-2 spontaneous differentiation in association with 
MET and CT gene expression:  
 
The gene expression profile of Caco-2 cells during differentiation was 
thoroughly analyzed by Sääf and Halbleib et al. [40,41]. By analyzing microarray gene 
expression data, these authors identified two distinct clusters named prepolarization 
(samples from 0 to 4 days) and polarization (samples from 4 to 26 days) which were 
formed by a switch in gene regulation at day 4. When the gene expression pattern of 
Caco-2 cells during differentiation was compared with normal colon and colorectal 
cancer samples, there were two clusters; tumor and normal epithelial cluster. While 
prepolarized cells remained in tumor clusters, polarized cells remained in normal 
epithelial cluster. Finally, they established that differentiated Caco-2 cells were more 
similar to normal epithelial cells compared to tumor cells [40,41]. In light of this data we 
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asked if the differentiation observed in Caco2 cells was similar to what would be 
expected in a mesenchymal to epithelial transition. We, therefore, studied alterations in 
gene expression in candidate epithelial and mesenchymal marker genes in this model by 
analyzing the GSE1614 dataset and using the EMT related gene list in colon cancer of 
Loboda et al [64,66]. We identified 3 mesenchymal marker genes; fibronectin, vimentin 
and transgelin and 3 epithelial marker genes; E-cadherin, claudin-4 and CDX-2 that 
were differentially expressed in Caco-2 differentiation. To validate these in silico 
findings, we performed qRT-PCR to show the gene expression differences of marker 
genes in the model at 4 time points; day 0 (100% confluency), 10, 20 and 30(fully 
differentiated). As the cells differentiated, epithelial marker genes (CDH1, CLDN4, 
CDX2) increased and mesenchymal marker genes (FN1, VIM, TAGLN) decreased in 
mRNA level in the analyzed two different differentiation sets (Figure 3.1.2 1). For both 
epithelial and mesenchymal marker genes, differential expressions were time dependent. 
mRNA expression study confirmed that cells were in  a differentiation from 
mesenchymal to epithelial phenotype. Changes in mRNA expression levels of both CT 
and EMT genes were statistically significant according to one way ANOVA test. The 
increase in CT gene expression was in concordance with the increase in epithelial 
marker gene expression and the decrease in mesenchymal marker gene expression.  
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Figure 3.1.2 1: CT gene mRNA levels increase concomitant with mesenchymal to 
epithelial transition.  
The relative mRNA expressions of mesenchymal marker genes (Fibronectin 1, Vimentin 
and Transgelin), epithelial marker genes (E-Cadherin, Claudin4 and Cdx2) and 3 CT 
genes (PAGE-2,-2B & SPANX-B) were shown during Caco-2 spontaneous differentiation 
at 2 different differentiation sets by q RT-PCR. GAPDH gene was used as endogenous 
control. Caco-2 cell line RNA at day 0 was used as reference sample in ΔΔCt 
calculations. In two independent sets of differentiation, the increase in CT gene 
expression was related with the increase in epithelial marker gene expression and the 
decrease in mesenchymal marker gene expression. The changes in gene expression 
levels were statistically significant and the p values were smaller than 0.0001 according 
to one way ANOVA test for all studied genes.   
 
In addition to the difference we observed in mRNA expression levels, we found 
down-regulation of fibronectin, transgelin and vimentin and up-regulation of SPANX-B 
and CDX-2 proteins as well, in three different differentiation experiments by western 
blotting technique (Figure 3.1.2 2).  
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Figure 3.1.2 2: Increase in CDX-2 (34 kDa, epithelial protein) and SPANX-B (12 
kDa, CT protein), the decrease in Transgelin (23 kDa), Fibronectin (263 kDa) and 
Vimentin (54 kDa) (mesenchymal proteins) at the protein level by western blot 
experiment in 3 different differentiation sets.  
 
Since the antibody of PAGE-2,-2B did not work in western blotting, 
immunofluorescence (IF) experiment was also performed. Although IF experiment was 
not for protein level determination, we achieved it as an alternative technique to western 
blotting. We performed IF experiments with all settings fixed throughout the experiment 
to be able to compare different time points. Confirming the western blots, mesenchymal 
proteins declined and epithelial protein inclined in the differentiation process (Figure 
3.1.2 3). CT proteins SPANX-B and PAGE-2,-2B accumulated in the cells as the cells 
differentiated (Figure 3.1.2 4). PAGE-2,-2B and SPANX-B proteins were localized at 
the nucleus, upon increase in protein levels cytoplasmic staining was also observed for 
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SPANX-B at day 30. Vimentin antibody stained the cells at the beginning of 
differentiation but, due to decrease in mRNA levels, staining completely disappeared at 
day 10 and 20. Fibronectin staining was also attenuated as cells differentiated. CDX2, an 
essential transcription factor for intestine epithelial cells, had nuclear staining pattern 
and increased in time dependent manner. Interestingly, heterogeneous staining patterns 
for both CT and EMT proteins were observed showing the heterogeneous population in 
Caco-2 cells during differentiation.      
 
 
Figure 3.1.2 3: Decrease in mRNA levels of mesenchymal marker genes (VIM, FN1 
and TAGLN) and increase in mRNA level of epithelial marker gene (CDX2) exist in 
protein level as well. 
Immunofluorescence staining results of MET marker proteins (red-Alexa 568) during 
Caco-2 spontaneous differentiation at day 0 and 20 were shown (40X). Cell nuclei were 
stained with DAPI. The decrease in Transgelin, Vimentin and Fibronectin protein levels 
and the increase in CDX2 protein level were observed from day 0 to day 20.  
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Figure 3.1.2 4: Increase in mRNA levels of CT genes (SPANX-B and PAGE-2,-2B) 
exists in protein level as well. 
Immunofluorescence staining results of CT proteins (green-Alexa 488) during Caco-2 
spontaneous differentiation at day 0 and 20 were shown (40X). Cell nuclei were stained 
with DAPI. The increase in CT protein levels were observed from day 0 to day 20 and 
the increase in SPANX-B protein level was more evident than the increase in PAGE-2,-
2B protein level.  
 
In order to show further evidence to this connection existing in mRNA and 
protein levels, we performed double staining in immunofluorescence (IF) experiment. 
One of the remarkable result that we obtained from IF staining, was divergent  staining 
pattern of CT proteins with mesenchymal proteins and convergent staining pattern of CT 
proteins with epithelial proteins. CT protein positive cells were mostly negative for 
mesechymal marker proteins (Vimentin and fibronectin). This observation was highly 
dramatic at day 0 images due to the abundance of mesenchymal proteins at the 
beginning of differentiation.  The co-existence of CT proteins with epithelial marker 
protein (CDX-2) in the corresponding cells was detected in day 0, 10 and 30 images 
(Figure 3.1.2 5, Figure 3.1.2 6, Figure 3.1.2 7, Figure 3.1.2 8, Figure 3.1.2 9, Figure 
3.1.2 10).  
51 
 
 
Figure 3.1.2 5: Double immunofluorescence staining at day 0 shows that vimentin 
positive cells are negative for SPANX-B protein and SPANX-B positive cells are 
negative for vimentin protein.  
(A) Cells were stained with α-SPANX-B antibody (green-Alex 488) and α-vimentin 
antibody (red-Alexa568) and DAPI was used to stain the nuclei. Representative images 
for day 0, day 10 and day 30 were shown (20X). SPANX-B protein localized in nucleus 
and vimentin protein had cytoskeletal staining pattern. At day 10, vimentin staining 
disappeared and vimentin and SPANX-B staining did not overlap due to the decrease of 
vimentin during differentiation. (B) The percent number of SPANX-B positive, vimentin 
positive and double positive cells were shown as bar graphs as a result of  counting the 
cells in 3 independent IF images. 
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Figure 3.1.2 6: Double immunofluorescence staining at day 0 shows that vimentin 
positive cells are negative for PAGE-2,-2B protein and PAGE-2,-2B positive cells 
are negative for vimentin protein.  
(A) Cells were stained with α-PAGE-2,-2B antibody (green-Alexa 488) and α-vimentin 
antibody (red-Alexa 568) and DAPI was used to stain the nuclei. Representative images 
for day 0, day 10 and day 30 were shown (20X). PAGE-2,-2B protein localized in 
nucleus and vimentin protein had cytoskeletal staining pattern. At day 10, vimentin 
staining disappeared and vimentin and PAGE-2,-2B staining did not overlap due to the 
decrease of vimentin during differentiation. (B) The percent number of PAGE-2,-2B 
positive, vimentin positive and double positive cells were shown as bar graphs as a result 
of  counting the cells in 3 independent IF images. 
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Figure 3.1.2 7: Double immunofluorescence staining shows that CDX2 protein co-
localizes with SPANX-B protein in the corresponding cells during differentiation. 
(A) Cells were stained with α-SPANX-B antibody (green-Alexa488) and α-CDX2 
antibody (red-Alexa568) and DAPI was used to stain the nuclei. Representative images 
for day 0, day 10 and day 30 were shown (20X). SPANX-B and CDX2 proteins co-
localized in the same cells. Both proteins had nuclear localizations. The co-localization 
was more pronounced at day 10 and at day 30 since levels of both proteins increased 
throughout the differentiation. (B) The percent number of SPANX-B positive, CDX2 
positive and double positive cells were shown as bar graphs as a result of  counting the 
cells in 3 independent IF images.  
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Figure 3.1.2 8: Double immunofluorescence staining shows that CDX2 protein co-
localizes with PAGE-2,-2B protein in the corresponding cells during differentiation. 
(A) Cells were stained with α-PAGE-2,-2B antibody (green-Alexa488) and α-CDX2 
antibody (red-Alexa568) and DAPI was used to stain the nuclei. Representative images 
for day 0, day 10 and day 30 were shown (20X). PAGE-2,-2B and CDX2 proteins co-
localized in the same cells. Both proteins have nuclear localizations. The co-localization 
was more pronounced at day 10 since levels of both proteins increased at day 10. (B) 
The percent number of PAGE-2,-2B positive, CDX2 positive and double positive cells 
were shown as bar graphs as a result of  counting the cells in 3 independent IF images. 
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Figure 3.1.2 9: Double immunofluorescence staining at day 0 shows that fibronectin 
positive cells are negative for SPANX-B protein and SPANX-B positive cells are 
negative for fibronectin protein. 
(A) Cells were stained with α-SPANX-B antibody (green-Alexa488) and α-fibronectin 
antibody (red-Alexa568) and DAPI was used to stain the nuclei. Representative images 
for day 0, day 10 and day 30 were shown (20X). SPANX-B protein localized in nucleus 
and fibronectin protein had cytoplasmic staining pattern. At day 10, fibronectin staining 
decreased. (B) The percent number of SPANX-B positive, fibronectin positive and 
double positive cells were shown as bar graphs as a result of  counting the cells in 3 
independent IF images.  
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Figure 3.1.2 10: Double immunofluorescence staining at day 0 shows that 
fibronectin positive cells are negative for PAGE-2,-2B protein and PAGE-2,-2B 
positive cells are negative for fibronectin protein.  
(A) Cells were stained with α-PAGE-2,-2B antibody (green-Alexa488) and α-fibronectin 
antibody (red-Alexa568), DAPI was used to stain the nuclei. Representative images for 
day 0, day 10 and day 30 were shown (20X). PAGE-2,-2B protein localized in nucleus 
and and fibronectin protein had cytoplasmic staining pattern. At day 10, fibronectin 
staining decreased. (B) The percent number of PAGE-2,-2B positive, fibronectin 
positive and double positive cells were shown as bar graphs as a result of  counting the 
cells in 3 independent IF images. 
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3.1.3 Epigenetic mechanisms underlying CT gene expression in Caco-2 spontaneous 
differentiation: 
A generally accepted epigenetic mechanism for CT gene expression regulation is 
promoter DNA methylation [1,5,11,21]. In order to understand whether promoter 
proximal DNA alterations correlated with CT gene upregulation during differentiation 
we carried out bisulphite sequencing of  CpG islands for PAGE-2 and PAGE-2B genes 
identified by searching 5500 bp length regions up to from -1500 bp from transcription 
start site (CpG Island Finder Software (http://cpgislands.usc.edu/)). For PAGE-2 and 
PAGE-2B genes, 8 and 10 CpG residues respectively were analyzed in the identified 
CpG islands. In all time points analyzed (day 0, 10 and 30), we identified that more than 
90% of the CpGs were methylated.  According to one way ANOVA test, the difference 
in methylation levels for PAGE-2 and PAGE-2B genes was not statistically significant. 
For SPANX-B gene, a promoter region that was previously analyzed was chosen for the 
bisulphite analysis. Demethylation of this region with critical specific 4 CpGs (CpG # 5, 
6, 7, 9) had previously been shown to be related with the gene expression [67,68].  And, 
of the 11 CpG residues analyzed within the SPANX-B promoter, no change in 
methylation was observed during the course of differentiation. Those CpGs previously 
reported as being critical for expression [67,68] were heavily methylated in our 
differentiation model at all-time points of differentiation. As a result, we conclude that 
for PAGE-2,-2B and SPANX-B genes, DNA hypomethylation is not the underlying 
epigenetic mechanism resulting in CT gene expression throughout the differentiation of 
Caco-2 cells (Figure 3.1.3 1).  
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Figure 3.1.3 1: The promoter proximal DNA regions of 3 CT genes are heavily 
hypermethylated.  
(A) Bisulphite sequencing within the promoter proximal regions of PAGE-2, PAGE-2B, 
and SPANX-B genes were shown. 8, 10, 11 CpG residues were analyzed for PAGE-2, 
PAGE-2B and SPANX-B genes, respectively, during Caco-2 differentiation at day 0, 10 
and 30 by bisulphite sequencing. (B) The methylated CpG residues were designated as 
black circles, and the unmethylated ones were designated as unfilled circles. The 
difference in DNA methylation was not significant for all genes and the p values were; 
for PAGE-2 p=0.1938, for PAGE-2B p=0.6110 and for SPANX-B p=0.7495 according to 
one way ANOVA test.  
 
Although bisulphite sequencing results seemed uninformative, as 5hmC residues 
are observed as 5mC residues with this method, we decided to analyze 5hmC residue in 
the promoters. The previously analyzed regions for CT genes were investigated for the 
occupancy of 5-hydroxymethylcytosine residue by hydroxymethylated DNA 
immunoprecipitation experiment.  Besides detecting hyroxymethylated DNA in the 
beginning of differentiation (day 0), we observed an increase in hydroxymethylation 
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levels in the following days of differentiation for both PAGE-2 and SPANX-B genes. 
The change in 5-hydroxymethylcytosine occupied DNA was statistically significant for 
PAGE-2 (Figure 3.1.3 2). 
 
Figure 3.1.3 2: The amount hydroxymethylated DNA increases in the promoter 
proximal regions of PAGE-2 and SPANX-B genes during Caco-2 spontaneous 
differentiation.  
The genomic DNAs isolated at day 0, 10 and 30 were sonicated and immunoprecipitated 
with α-5hmC antibody. The immunoprecipitated DNA was amplified by the primers 
spanning the promoter proximal regions of PAGE-2 and SPANX-B genes by SYBR based 
q RT-PCR. Preimmune serum was used as the negative control in the experiment. PCR 
result was analyzed by percent input method. The change in hydroxymethylation level 
for PAGE-2 was statistically significant (p= 0.001). Although a similar trend was 
observed for SPANX-B hydroxymethylation levels, it was not significant (p=0.0773).  
 
  Increases in 5-hydroxymethylcytosine levels have been previously associated 
with increased TET1,-2,-3 expression levels [56,69]. We, therefore, analyzed mRNA 
expression levels of those enzymes responsible for 5hmC DNA generation during Caco2 
spontaneous differentiation, and observed that both TET1,-2,-3 genes were induced 
(Figure 3.1.3 3).  
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Figure 3.1.3 3: mRNA levels of TET genes (TET1, TET2, TET3), responsible for 
5hmC residue generation, increase during Caco-2 spontaneous differentiation. 
Relative mRNA expressions of various CT genes were shown during Caco-2 
spontaneous differentiation at 4 different time points by SYBR based q RT-PCR. 
GAPDH gene was used as endogenous control. The change in mRNA levels of TET1 
and TET2 genes was statistically significant and the p values were; for TET1 p=0.0304, 
for TET2 p=0.0093. (For TET3 p value was 0.0720 and was not statistically significant) 
 
Among three TET enzymes, TET2 showed the most dramatic change. When we 
investigated the change in protein level by Western blotting, we did not find a difference 
in the amount of the full length TET2 protein (220 kDa) using one commercial antibody. 
However, with a second antibody generated by Abcam, we detected a 25kDa band 
whose quantity increased through the differentiation process, as observed in 3 different 
differentiation sets consistently (Figure 3.1.3 4). To ensure the specificity of the band, 
we incubated TET2 antibody with its specific blocking peptide during the western blot 
experiment. Since the band disappeared with blocking with the specific peptide we were 
certain about the 25kDa band belonging to TET2 (Figure 3.1.3 4).  To explain the 25kD 
band, we performed bioinformatic analyses but were unable to identify an alternatively 
spliced TET2 mRNA that could translate a 25kDa peptide. Since we knew from the 
literature that TET proteins could be post translationally modified by calpains, we 
performed western blotting with Caco-2 lysates treated with a general Ca
+2
 chelator 
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(BAPTA-AM) which is expected to inhibit most calpains, as they are Ca
+2
.dependent. 
Although BAPTA-AM treatment did not result in the loss of the  25kDa band, a TET2 
peptide with a higher molecular weight appeared, which is likely to be an incompletely 
processed version of TET2 (Figure 3.1.3 5). Thus we conclude that TET2 might be 
cleaved with a Ca
+2
 dependent calpain.   
 
Figure 3.1.3 4: A possible small variant of TET2 protein is found to be increased in 
Caco-2 differentiation consistently in 3 different differentiation sets.  
(A) The predicted band at 220 kDa could not be detected by Abcam (UK) anti-Tet2 
antibody (ab94580) but a band close to 25 kDa was detected consistently increased 
during the differentiation in 3 different sets. (B) The band was specific to TET2 protein 
since it disappeared when TET2 peptide was introduced in the antibody incubation step.  
The protein level of full length TET2 does not increase in Caco-2 differentiation.  
(C) The predicted band at 220 kDa was identified by Active Motif anti-TET2 antibody 
(61389) and the level did not increased as expected similar to the small variant. The 
small variant could not be detected with this antibody.  
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Figure 3.1.3 5: A possible truncated form of TET2 is generated with Ca
+2
 
dependent calpains. 
Caco-2 cells at day 0 and day10 time points were incubated with Ca
+2
chelator BAPTA-
AM which inhibited calpains` activity. Though 25kDa band did not disappear 
significantly, a larger molecular weight band appeared showing the cleavage by 
calpains.  
  
When we double stained Caco-2 cells with TET2 and CT antibodies, surprisingly 
we observed that cells having PAGE-2,-2B or SPANX-B proteins had TET2 protein at 
the same time and vice versa (Figure 3.1.3 6). Based on this data, we think the truncated 
TET2 form we identified might be functional.  
In summary, as we could show an accumulation in 5hmC levels at promoter 
proximal regions of the CT genes, an increase in the expression levels of TET genes, and 
the colocalization of TET2 protein with CT proteins, we hereby demonstrate - to our 
knowledge - for the first time the involvement of 5-hydroxymethylcytosine in CT gene 
expression.  
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Figure 3.1.3 6: Double immunofluorescence staining shows that TET2 protein co-
localizes with SPANX-B and PAGE-2,-2B proteins in Caco-2 cells during 
differentiation.  
(A) Cells were stained with α-SPANX-B antibody (green-Alexa488) and (B) α-TET2 
antibody (red-Alexa568) or α-PAGE-2,-2B antibody (green-Alexa488) and α-TET2 
antibody (red-Alexa568) and DAPI was used to stain the nuclei. Representative images 
for day 20 were shown (40X). Both proteins had nuclear localizations. In both of the 
staining experiments, TET2 positive cells were positive for SPANX-B and PAGE-2,-2B. 
The percent number of (C) SPANX-B positive or (D) PAGE-2,-2B positive , TET2 
positive and double positive cells were shown as bar graphs as a result of  counting the 
cells in 3 independent IF images. 
 
 Since the role of histone modifications is known to have a role in CT gene 
expression, we analyzed inhibitory chromatin marks on the promoters of CT genes as 
well.  Interestingly, as the cells differentiated and expressed CT genes, repressive 
chromatin marks such as HP1, EZH2 and H3K27me3 diminished (Figure 3.1.3 7).  The 
increase in 5hmC levels on DNA might relate to the loss of HP1, EZH2 and H3K27me3 
marks from chromatin and led to CT gene expression.     
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Figure 3.1.3 7: Binding of (A) EZH2, H3K27Me3 and (B) HP1 to the promoters of 
PAGE-2B, PAGE-2 and SPANX-B decreases during differentiation shown by ChIP 
with the indicated antibodies or control IgG. 
Figures are representative of three independent biological replicates. * p<0.05, ** 
p<0.01, *** p<0.001 compared to IgG. # p<0.05, ## p<0.01, ### p<0.001 compared to 
Day 0. (These experiments were performed by Dr. Aslı Sade Memişoğlufrom METU)  
 
 Up to this point, we showed that CT genes were expressed concomitant with an 
increase in 5hmC levels on DNA and the dissociation of repressive chromatin marks, as 
the Caco-2 cells gained epithelial properties during differentiation. We next asked if 
these events could be reversed upon dedifferentiating Caco-2 cells. Indeed, when Caco-2 
cells were dedifferentiated (as evidenced by the decrease in sucrose isomaltase 
expression) by detaching and reseeding differentiated cells at low seeding density, CT 
genes were down-regulated and epithelial to mesenchymal transition took place together 
with a decrease in TET gene expression  (Figure 3.1.3 8).  
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Figure 3.1.3 8: As the dedifferentiation occurs, cells gain mesenchymal character, 
down-regulate CTs and TET enzymes at the same time.  
(A) Caco-2 cells were dedifferentiated according to decrease in sucrose isomaltase 
mRNA expression. (B) Relative mRNA expressions of CT genes, CDX2 (epithelial 
marker), TAGLN (mesenchymal marker) and (C) TET genes were shown during Caco-2 
dedifferentiation at 5 days later the reseeding by SYBR based q RT-PCR. GAPDH gene 
was used as endogenous control. 
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3.2 REGION SPECIFIC EPIGENETIC MECHANISMS OF CANCER 
TESTIS (CT) AND CT PROXIMAL GENE EXPRESSION 
3.2.1 Analysis of CT proximal genes down-regulated in cancer by CGAP: 
If epigenetic changes that relate to CT gene expression are contained within a 
region in the genome that includes CT genes but excludes others, then there should be 
clear boundaries between such regions if they are in close proximity. To identify such 
regions we hypothesized that we could study CT-proximal “non-CT genes”. To identify 
such genes previously in our lab, by using SAGE and EST databases of Cancer Genome 
Anatomy Project (CGAP) and analyzing libraries of cancerous versus healthy tissues, 59 
genes on chromosome X were found to be down-regulated in cancer by Aydan Bulut. 
Among 59 genes, 8 of them were in close proximity of a CT gene. Since the down-
regulation of 2 genes were verified in lung and colon cancer panels by RT-PCR, we 
conducted our further experiments with these 2 CT proximal genes down-regulated in 
cancer; ALAS2( aminolevulinate, delta-, synthase 2) and CDR1 ( cerebellar 
degeneration-related protein 1).  In Figure 3.2.1 1, genomic alignments of ALAS2 and 
CDR1 genes on chromosome X and their proximities to the CT genes are shown.   
 ALAS2 is about 50 kb away from PAGE-2,-2B genes. CDR1 is about 200 kb 
away from SPANX-B genes. SPANX-B1,-B2 genes are allelic variant of SPANX-B gene 
that result with one amino acid substitution in the encoded protein [70].  PAGE-2,-2B 
and SPANX-B genes form a repeat region on chromosome X. 
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Figure 3.2.1 1: The genomic location of ALAS2 and CDR1 genes with respect to 
proximal cancer-testis antigens; PAGE-2,-2B and SPANX-B respectively. 
 
3.2.2 The down-regulation in mRNA expression of CT proximal genes; ALAS2 and 
CDR1 and CT gene expression in cancer:  
Expression analyses of ALAS2 and CDR1 genes were performed by predesigned 
Taqman probes based q RT-PCR technique.  As shown in Figure 3.2.2 1and Figure 3.2.2 
3, ALAS2 and CDR1 were found to be down-regulated in a panel of colon and lung 
cancer cell lines compared to normal healthy tissues. ALAS2 was expressed most at 
placenta and least at colon but, including the colon tissue it was expressed in all of the 
tested healthy tissues. CDR1 was also expressed in all normal tissues at different levels.  
To sum up, ALAS2 and CDR1 genes were found to be expressed constitutively by all of 
healthy tissues that were analyzed. The significant down-regulation of ALAS2 and CDR1 
genes in cancer cell lines compared to healthy tissues was demonstrated as seen in 
Figure 3.2.2 1and Figure 3.2.2 3. Except NCI-H69 which still dramatically down-
regulated ALAS2 gene, none of the tested cancer cell lines had ALAS2 mRNA 
expression. The significant down-regulation in CDR1 gene was also shown in colon and 
lung cancer cell lines compared to normal counterparts.     
When mRNA expressions of CT genes were analyzed in this panel, they were 
mainly detected in testis and placenta among normal healthy tissues as expected.  
PAGE-2 and 2B were also found to be weakly expressed in some normal tissues since 
some CT genes were classified as testis selective. PAGE-2,-2B and SPANX-B were 
expressed in cancer cell lines at comparable or higher levels than the expression levels in 
testis (Figure 3.2.2 2and Figure 3.2.2 4). Finally these extensive expression analyses 
confirmed the opposite expression patterns of CT and CT proximal genes in normal 
tissues versus cancer cell lines that were previously identified by CGAP analysis.   
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Figure 3.2.2 1: The mRNA expression of ALAS2 gene is shown in normal tissues 
and a panel of colon and lung cancer cell lines by Taqman probe based q RT-PCR. 
GAPDH gene was used as endogenous control.  Although ALAS2 expression was 
detected in variable amounts in all healthy tissues, in none of the tested lung and colon 
cancer cell lines ALAS2 mRNA expression existed.  
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Figure 3.2.2 2:  The mRNA expressions of PAGE-2,-2B genes proximal to ALAS2 
are shown in normal tissues and a panel of colon and lung cancer cell lines by 
Taqman probe q RT-PCR.  
GAPDH gene was used as endogenous control. In addition to testis and placenta, PAGE-
2,-2B expression was detected in some of the normal tissues. Most of the cancer cell 
lines were positive for PAGE-2,-2B expression.  
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Figure 3.2.2 3: The mRNA expression of CDR1 gene is shown in normal tissues and 
a panel of colon and lung cancer cell lines by Taqman probe q RT-PCR. 
GAPDH gene was used as endogenous control.  The significant down-regulation in 
CDR1 mRNA expression was detected in a large panel of lung and colon cancer cell 
lines compared to normal tissues.  
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Figure 3.2.2 4: The mRNA expression of SPANX-B gene proximal to CDR1 is 
shown in normal tissues and a panel of colon and lung cancer cell lines by Taqman 
probe q RT-PCR.  
GAPDH gene was used as endogenous control. SPANX-B expression was observed in 
testis and placenta as a classical CT gene among normal tissues. Some of the cancer cell 
lines expressed SPANX-B at levels even higher than testis tissue.   
 
3.2.3 The promoter proximal DNA methylation of ALAS2 and CDR1 genes in 
normal tissues and colon and lung cancer cell lines: 
In order to identify the promoter methylation status of ALAS2 and CDR1, a 
region between -2500 to +2500 bp from transcription start site was analyzed to find a 
CpG island for each gene. However, none of the tested CpG island prediction programs; 
CpG Island Search Software (http://cpgislands.usc.edu/) and EMBOSS CpG Plot 
Software (http://www.ebi.ac.uk/Tools/seqstats/emboss_cpgplot/), could predict a CpG 
island in 5000 bp length region for both ALAS2 and CDR1 genes. Due to the absence of 
CpG islands, we focused on individual CpG residues that were covered in this 5000 bp 
length region. The primers were designed to span maximum number of CpGs and not to 
hit methylated or unmethylated CpGs in order to eliminate bias in PCR reaction. Due to 
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the limitation of bisulphite sequencing technique; in 3 different regions, totally 10 and 9 
CpG residues respectively for ALAS2 and CDR1 genes could be analyzed as shown in 
Figure 3.2.3 1and Figure 3.2.3 2.  
The bisulphite sequencing experiment was performed with genomic DNAs of 
cell lines that did not have ALAS2 and CDR1 expression and the genomic DNAs of 
normal male colon, female colon and lung tissues. The sum of sequencing results are 
shown as percent methylation in Table 3.2.3 1 and  Table 3.2.3 2. According to these 
results, the promoter of ALAS2 gene was highly methylated in normal colon tissues. The 
results of q RT-PCR experiment  showed that colon was one of the tissues having low 
ALAS2 mRNA expression. Thus, we suggested that promoter methylation of ALAS2 in 
colon tissue might be related with this low level of expression. The promoter region of 
ALAS2 in SK-LC-17 and HCT116 cancer cell lines was hypermethylated. However in 
LoVo and SW620, the region was hypomethyated even though none of the cell lines had 
ALAS2 mRNA expression. CDR1 promoter in normal colon tissues was hypermethylated 
although colon had CDR1 expression in significant amounts. CDR1 promoter was highly 
hypomethylated in all of the cancer cell lines lacking CDR1 expression. For both ALAS2 
and CDR1 gene, normal healthy tissues expressing the genes had methylated promoters 
wehereas cancer cell lines lacking the gene expression had low levels of promoter 
methylation. In conclusion, the promoter methylation status of  ALAS2 and CDR1 genes  
did not correlate with the gene expression levels. 
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Figure 3.2.3 1: The organization of ALAS2 gene; promoter, exon-intron structure 
and bisulphite sequencing result of the analyzed CpG residues are shown.  
(A) Dark black boxes denote exons, lines between them denote introns, red and grey 
lollipops denote CpG residues that are analyzed and not analyzed respectively. The CpG 
residues of ALAS2 gene were analyzed in three regions, one in the promoter, one in the 
first exon and one in the first intron. (B) The bisulphite sequencing results were shown 
in circle designation for normal healthy lung and colon tissues versus SKLC-17 lung 
cancer cell line and HCT116, SW620, LoVo colon cancer cell lines. The degree of 
methylation was revealed with the darkness of the circle.   
 
 
 
 
 
 
 
 
74 
 
Table 3.2.3 1: The methylation status of ALAS2 promoter in analyzed normal 
tissues and cancer cell lines shown as percent methylation 
 
 
 
 
 
 
 
 
 
 
 
 
% METHYLATION ALAS2.1 ALAS2.2 ALAS2.3 
NORMAL LUNG  85.00%  88.90%  85.70% 
SK-LC-17 100.00% 96.67% 97.22% 
% METHYLATION ALAS2.1 ALAS2.2 ALAS2.3 
NORMAL COLON_MALE 100.00% 80.00% 96.97% 
NORMAL COLON_FEMALE 84.09% 84.62% 77.78% 
HCT116 100.00% 78.79% 100.00% 
LOVO 27.27% 33.33% 48.48% 
SW620 10.00% 48.72% 71.79% 
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Figure 3.2.3 2: The organization of CDR1 gene; promoter, exon-intron structure 
and bisulphite sequencing result of the analyzed CpG residues are shown.  
(A) Dark black boxes denote exons, lines between them denote introns, red and grey 
lollipops denote CpG residues that are analyzed and not analyzed respectively. The CpG 
residues of CDR1 gene were analyzed in three regions, first two in the promoter, and the 
last one in the first exon. (B) The bisulphite sequencing results were shown in circle 
designation for normal healthy lung and colon tissues versus SKLC-17 lung cancer cell 
line and HCT116, SW620, LoVo colon cancer cell lines. The degree of methylation was 
revealed with the darkness of the circle.   
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Table 3.2.3 2: The methylation status of CDR1 promoter in analyzed normal tissues 
and cancer cell lines shown as percent methylation  
 
 
 
 
 
 
 
 
 
3.2.4 The response of CT proximal genes; ALAS2, CDR1 and CT genes; PAGE-2,-
2B, SPANX-B to 5-aza-2’-deoxycytidine treatment in cancer cell lines: 
 To have a complete understanding in epigenetic mechanisms resulting up-
regulation of CT gene expression and down-regulation of CT proximal gene expression 
in cancer, we treated cancer cell lines with DNMTi, 5-aza-2’-deoxycytidine, for 72 
hours. As seen in Figure 3.2.4 1; upon 5-aza-2’-deoxycytidine treatment, PAGE-2,-2B 
and SPANX-B genes were up-regulated in significant amounts compared to untreated 
controls in HCT116 and SK-LC-17 cell lines. On the other hand, the expressions of 
ALAS2 and CDR1 genes did not differ in any of the analyzed cell lines.     
 
% METHYLATION CDR1.1 CDR1.2 CDR1.3 
NORMAL LUNG  97.20%  100.00%  93.30% 
SK-LC-17 0.00% 40.00% 0.00% 
% METHYLATION CDR1.1 CDR1.2 CDR1.3 
NORMAL COLON_MALE 90.91% 97.92% 82.05% 
NORMAL COLON_FEMALE 48.72% 42.22% 31.11% 
HCT116 66.67% 66.67% 16.67% 
LOVO 20.00% 29.17% 23.33% 
SW620 0.00% 6.06% 2.56% 
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Figure 3.2.4 1: The response of CT genes and CT proximal genes to 5-aza-2’-
deoxycytidine treatment is showed by q RT-PCR.  
PAGE-2,-2B and SPANX-B genes were induced by 5-aza-2’-deoxycytidine treatment in 
cancer cell lines whereas ALAS2 and CDR1 did not respond 5-aza-2’-deoxycytidine 
treatment. 
 
3.2.5 The promoter proximal DNA hydroxymethylation of ALAS2 and CDR1 genes 
in normal tissues, colon and lung cancer cell lines: 
The bisulphite sequencing results were unable to clarify the difference in 
epigenetic basis of expression of CT and CT proximal genes in healthy versus cancerous 
condition, so we searched for other DNA modifications having effect on gene 
expression. 5hmC, a newly identified epigenetic mark on DNA, might be identified as 
methylated CpG in bisulphite sequencing experiment. Although the hypomethylated 
promoters of cancer cell lines could not be explained with this new residue, we believed 
the identified hypermethylated promoters in normal tissues having ALAS2 and CDR1 
expression might contain 5hmC instead of 5mC. To detect 5hmC residue on the 
promoters, we performed q RT-PCR following hydroxymethylated DNA 
immunoprecipitation specific to the analyzed region in bisulphite experiment. PCR 
primers for ALAS2 gene hit 3
rd
 region and for CDR1 gene hit 2
nd
 region. As predicted, 
normal lung and colon tissues had high amount of 5hmC containing DNA compared to 
cancer cell lines. Interestingly, when the promoters of CT genes were examined for 
5hmC residue, cancer cell lines had higher amounts of 5hmC compared to normal 
tissues (Figure 3.2.5 1).  
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Even though, DNA methylation was insufficient to explain the gene expression 
pattern of ALAS2 and CDR1, CT proximal gene expression in normal tissues and CT 
expression in cancer cell lines might be described with the abundance of 5hmC residue 
on promoter proximal regions.  
 
 
 
 
 
 
 
 
 
Figure 3.2.5 1: The amount hydroxymethylated DNA in the promoter proximal 
regions of CT genes and CT-proximal genes are shown.  
The genomic DNAs were sonicated and immunoprecipitated with α-5hmC antibody. The 
immunoprecipitated DNA was amplified by the primers spanning the promoters of CT 
and CT proximal genes by SYBR based q RT-PCR. Preimmune serum was used as the 
negative control in the experiment. q RT-PCR result was analyzed by percent input 
method. The immunoprecipitated DNA amount was high in normal tissues for CT 
proximal genes and in cancer cell lines for CT genes in consistence with the expression 
patterns. 
 
3.2.6 The gene expression of TET enzymes in normal tissues and colon and lung 
cancer cell lines: 
Hydroxymethylated DNA immunoprecipitation results showed that the 
hydroxymethylation was gene specific event since we detected hydroxymethylated DNA 
at different abundance in the same sample for different genes. Even though this 
observation, we wondered the expressions of TET , 5hmC generating, enzymes. For 
colon cancer cell lines, TET enzymes were down-regulated according to normal colon 
tissue except TET1 enzyme in SW620 cell line. For lung cancer cell lines, all enzymes 
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were up-regulated in SK-LC-17 (Figure 3.2.6 1). Thus we concluded that instead of TET 
enzymes` expression levels, the position of hydroxymethylcytosine residue was relevant 
with the gene expression.     
 
Figure 3.2.6 1: The mRNA levels of TET genes (TET1, TET2, TET3) in colon cancer 
and lung cancer cell lines with respect to normal counterparts.  
The relative mRNA expressions of three TET enzymes were shown by SYBR based q 
RT-PCR. GAPDH gene was used as endogenous control.  
 
3.2.7 The result of ectopic expressions of ALAS2 and CDR1 genes in cancer cell 
lines in cell viability manner:   
 Previously we showed that ALAS2 and CDR1 genes were notably down regulated 
in cancer. Due to the apparent down-regulation in cancer, we asked whether these genes 
had tumor suppressor abilities. To answer this question, we ectopically expressed these 
genes by using tetracycline (Tet) inducible expression system in HCT116 and SK-LC-17 
cell lines. Before transfection experiments, we generated Tet repressor expressing stable 
clones and selected the clones expressing Tet repressor in highest amount and continued 
our experiments with them (Figure 3.2.7 1). After transient transfection, we verified that 
ALAS2 gene was overexpressed in tetracycline induced clones, as shown in Figure 3.2.7 
2. We could not eliminate the leaky expression in non-induced cells although we used 
tetracycline reduced serum for this experiment.  We conducted MTT cell viability 
experiment after transient transfection in clones either transfected with ALAS2 or CDR1 
transgenes or with empty vector both in the presence or absence tetracycline.  In results 
of ectopic expression of ALAS2 and CDR1 genes, no significant difference in cell 
viability compared to control cells transfected with empty vector was observed, as seen 
in Figure 3.2.7 3. 
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Figure 3.2.7 1: 3 candidate clones are identified as a result of β-Galactosidase 
staining experiment performed after pcDNA4/TO/lacZ transfection to stable clones 
expressing Tet repressor.  
pcDNA3.1lacZ was used as positive control to determine transfection efficiency. 
Although the leaky expression was seen in the absence of tetracycline, 
HCT116.6TR_Clone4, HCT116.6TR_Clone9 and SKLC17.6TR_Clone5 were the three 
clones having the highest induction of lacZ gene with tetracycline addition.  
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Figure 3.2.7 2: ALAS2 gene expression in tetracycline treated clones compared to 
untreated and untransfected clones.  
ALAS2 gene was cloned in pcDNA/4TO vector. The transfection was performed to two 
stable clones expressing tet repressor via Mirus TransIT-LT1 transfection reagent 
transiently. The transfection efficiency in this experiment is 45% for HCT116.6TR clone 
9 and 13% for SK-LC-17.6TR clone 5. Although the leaky expression existed in the 
absence of tetracycline, the induction of ALAS2 was evident with the addition of 
tetracycline. ALAS2 expression was much more than the physiological levels.   
   
82 
 
A
LA
S
2 
+T
E
T
A
LA
S
2 
-T
ET
pc
D
N
A
4T
O
 +
TE
T
pc
D
N
A
4T
O
 -T
E
T
0
25
50
75
100
125
HCT116.6TR Clone 9
%
 V
IA
B
IL
IT
Y
A
LA
S
2 
+T
E
T
A
LA
S
2 
-T
ET
pc
D
N
A
4T
O
 +
TE
T
pc
D
N
A
4T
O
 -T
E
T
0
25
50
75
100
125
150
175
200
SK-LC-17.6TR Clone 5
%
 V
IA
B
IL
IT
Y
C
D
R
1 
+T
E
T
C
D
R
1 
-T
E
T
pc
D
N
A
4T
O
 +
TE
T
pc
D
N
A
4T
O
 -T
E
T
0
25
50
75
100
125
150
175
HCT116.6TR Clone 9
%
 V
IA
B
IL
IT
Y
C
D
R
1 
+T
E
T
C
D
R
1 
-T
E
T
pc
D
N
A
4T
O
 +
TE
T
pc
D
N
A
4T
O
 -T
E
T
0
25
50
75
100
125
150
175
200
SK-LC-17.6TR Clone 5
%
 V
IA
B
IL
IT
Y
 
Figure 3.2.7 3: The cell viability results are measured by MTT assay after ectopic 
expression of ALAS2 and CDR1 gene.   
ALAS2 and CDR1 genes were cloned in pcDNA/4TO vector. The transfections were 
performed to two stable clones expressing tet repressor via Mirus TransIT-LT1 
transfection reagent transiently. With the addition of tetracycline and the induction of 
transgenes, the cell viability values did not change.   
 
3.2.8 ALAS2 and CDR1 expression in Caco-2 spontaneous differentiation model 
Previously, we showed that PAGE-2,-2B and SPANX-B genes were dynamically 
expressed in Caco-2 spontaneous differentiation. Since we analyzed CT proximal gene 
expression (ALAS2 and CDR1) in association with CT gene expression (PAGE-2,-2B 
and SPANX-B) in cancer cell lines, we examined ALAS2 and CDR1 gene expression in 
Caco-2 spontaneous model as well. We determined that in addition to the up-regulation 
of CT genes, proximal genes were also up-regulated in the model contrary to the 
situation in cancer cell lines. We speculated that Caco-2 spontaneous differentiation 
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model established a window of MET where both CT and CT proximal genes were 
simultaneously expressed.  
 
Figure 3.2.8 1: ALAS2 and CDR1 gene expression in Caco-2 spontaneous 
differentiation  
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3.3 GENE EXPRESSION INSIDE AND OUTSIDE OF A CANCER TESTIS 
GENE-CONTAINING REPEAT REGION 
3.3.1 Uncoordinated expression of NY-ESO-1, IκBG and the noncoding RNAs in 
NY-ESO-1 containing repeat region: 
 To test whether the repeat regions that were composed of CT genes were 
boundaries of region specific epigenetic mechanisms and forming a 3 dimensional loop 
structure to control coordinate CT gene expression, we focused on NY-ESO-1 containing 
repeat region. We chose NY-ESO-1 region due to the simplicity of the region. In addition 
to IκBG and NY-ESO-1 genes, we identified various noncoding RNAs coded within the 
repeat region and one noncoding RNA coded outside the repeat region (Figure 3.3.1 1). 
By analyzing expressions of genes within the repeat region and outside the repeat 
region, a similar expression pattern of noncoding RNAs with NY-ESO-1 expressions was 
investigated.  For q RT-PCR experiments, in addition to NY-ESO-1 positive (Mahlavu, 
SK-LC-17 and MDA-MB157) and negative cell lines (HCT116, SW20 and MCF-7), 5-
aza-2’-deoxycytidine treated NY-ESO-1 negative cell lines were used.  No significant 
difference in noncoding RNA expression between NY-ESO-1 positive and negative cell 
lines was observed.  The only gene induced with 5-aza-2’-deoxycytidine was NY-ESO-1 
in the repeat region (Figure 3.3.1 2). Thus, we concluded that there was not a clear 
association in gene expression within the repeat region. NY-ESO-1 was controlled in an 
exclusive manner according to DNA methylation. This information led us to think that 
the proposed 3 dimensional structure formed by repeat regions may not be critical as an 
epigenetic regulation mechanism in CT gene expression.          
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Figure 3.3.1 1: The localization of primers hitting IκBG, NY-ESO-1 and 3 
noncoding RNA genes in NY-ESO-1 repeat region.  
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Figure 3.3.1 2: The expressions of noncoding RNAs in repeat region, IκBG and NY-
ESO-1 in NY-ESO-1 positive (Mahlavu, SK-LC-17 and MDA-MB157) and negative 
cell lines (HCT116, SW20 and MCF-7) are analyzed by q RT-PCR.  
The expression of genes within the repeat region did not correlate with NY-ESO-1 
expression. 5-aza-2-deoxycytidine treatment of NY-ESO-1 negative cell lines induced 
only NY-ESO-1 in repeat region.  
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4 DISCUSSION AND CONCLUSION 
 
In our Caco-2 spontaneous differentiation model, we detected dynamic and 
reversible expressions of 3 CT genes (PAGE-2,-2B and SPANX-B). Up to now, the only 
mechanism to induce CT gene expression was treating the cells with either DNA 
hypomethylating agents or histone deacetylase inhibitors. For the first time, we showed 
the induction of 3 CT genes in a differentiation model without treatment. Expression 
levels of PAGE-2,-2B and SPANX-B were far beyond the expression levels in colorectal 
cancer tumors (unpublished data). The overexpression of CT genes in various tumors is 
aimed in order use them in immunotherapeutic approaches in cancer treatments for 
many years [5]. Because of CT immunotherapy attempts, the induction of these CT 
genes without chemical treatment might be critical, if an in vivo process mimicking this 
differentiation can be generated. The reason of detecting CT genes among the rest of the 
other CT genes might be the existence of basal expressions of PAGE-2,-2B and SPANX-
B genes at the beginning of differentiation. Also, SPANX-B gene was previously 
characterized as being expressed in later stages of spermatogenesis such as late 
spermatids and spermatozoa whereas many other CT genes were detected in 
spermatagonia or primary spermatocytes [8]. Although the expression patterns of PAGE-
2,-2B genes were not considered in that study, we believe that PAGE-2,-2B may differ 
from the other CT genes according to gene expression pattern in the light of our existing 
data.  
We showed and verified that Caco-2 spontaneous differentiation model was a 
mesenchymal to epithelial model where the mesenchymal cancer cells differentiated and 
resembled to normal intestinal epithelial cells. Our result supported previously 
performed micro array studies [41,64,71].  
CT gene expression in relation to either mesenchymal or epithelial phenotype of 
the cell is a controversial issue for the literature. Some studies claim that CT gene 
expression mainly associates with the mesenchymal and migratory phenotype of the 
cells [26,28,29,72-75]. The information comes from the analysis of CT gene expression 
in cancer stem cells and either knockdown or overexpression studies of CT genes. On 
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the other hand various studies argue as CT gene expression being a part of epithelial 
phenotype of the cells [35,36,76,77].  In the study conducted by Gupta et al., the gene 
expression in transformed HMLE in response of either salinomycin (shown to be 
effective on mesenchymal type of cells in tumor) or paclitaxel (shown to be effective on 
epithelial type of cells in tumor) was analyzed. MAGE-A1 gene was up-regulated in 
salinomycin treatment which eliminated the mesenchymal cells and down-regulated in 
paclitaxel treatment which eliminated the epithelial cells [35]. Similarly, the result of 
another study done by Thomson et al. claimed that CT (SPANXA1,-A2, SPANX-B1,-B2, 
SPANXC, MAGEA8) gene expression was diminished in two EMT models generated by 
stable transfection of Snail gene and TGF-β exposure [36].  In addition to up-regulation 
of MAGE-A1 gene in epithelial enriched population and down-regulation of various CT 
genes in two important EMT models, CT gene expression identified in our MET model 
proved that CT gene expression might be related with epithelial phenotype during the 
EMT process.   
Although promoter DNA hypomethylation is a well-established epigenetic event 
leading expressions of most CT genes, we could not identified difference in DNA 
demethylation in promoter proximal regions of analyzed 3 CT genes. We knew from our 
previous data, DNA hypomethylating agent and histone deacetylase inhibitor treatments 
resulted with the induction of various CT genes not only PAGE-2,-2B and SPANX-B in 
many cancer cell lines as well as in Caco-2 cells. The observed over-expression of 
PAGE-2,-2B and SPANX-B genes in the model had to be somewhat different than simple 
DNA hypomethylation or histone modification in that manner.  
When we analyzed CT promoter proximal regions for DNA hydroxymethylation, 
not only we observed that the highly methylated promoter proximal DNA was in fact 
hydroxymethylated since we immunoprecipitated  it, but also we showed 
hydroxymethylation levels for the promoters of PAGE-2 and SPANX-B genes increased 
at day 10 after the differentiation started. For the first time, we identified 
hydroxymethylation as a new epigenetic mechanism in CT gene expression in addition 
to DNA hypomethylation and histone modifications. Effect of 5hmC containing DNA 
on gene expression was shown in previous studies [43,69] . 5hmC can be converted 
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further to 5-formylcytosine (5-fC) and 5-carboxycytosine  (5-caC)  and both residues are 
recognized as unmethylated cytosine in bisulhite sequencing [56].Therefore , we are sure 
that 5hmC that we detected is not DNA demethylation intermediate or any other 
residues.  Related with the increase in 5hmC levels on the promoter proximal regions, 
we also detected an increase in mRNA levels of TET enzymes that generate 5hmC 
residues from existing 5mC residues. Interestingly, there was a clear co-localization of 
TET2 protein with CT proteins in the heterogeneous Caco-2 cell population during 
differentiation. Studies trying to map 5hmC residue in the genome suggested that 5hmC 
mainly localized at euchromatin, at gene bodies of actively transcribed genes and 
promoters of polycomb repressed development related genes in pluripotent stem cells 
showing the function of 5hmC on gene expression [43,78]. 5hmC residue was detected 
in various differentiated human tissues and its levels were diminished in cancerous 
tissues [51,52]. Those results claimed that 5hmC not only have an effect on gene 
expression in pluripotent stem cells but also in somatic tissues and in carcinogenesis. 
The association of CT gene expression to 5hmC occupancy on promoter proximal 
regions of CT genes was in concordance with the literature in this manner. Decrease in 
5hmC levels and reduction in expression of TET enzymes in cancer tissues compared to 
normal counterparts supported  our data while cancer like Caco-2 cells were resembling 
to normal epithelial cells during differentiation [52]. Previously, role of TET2 and 5hmC 
residue on CpG dense region of HOXA cluster was shown in retinoic acid induced 
NTERA2 D1 differentiation. They not only showed activation of HOXA cluster with 
5hmC enrichment on the region upon differentiation but also established the important 
function of TET2 on HOXA activation by using siRNA mediated depletion of TET2 and 
TET2 knockout mouse model. [69] Here in our Caco-2 spontaneous differentiation 
model, we showed the expression of CT genes with respect to 5hmC abundance on the 
promoter proximal regions and the clear colocalization of TET2 protein with CT 
proteins in CT expressing cells in a similar way. Vitamin C supplementation to ESCs 
also resulted with TET activity, an increase in the level hmC on DNA and activation of 
germline genes. Those observations were also very consistent with our results [79].     
For the first time, we claimed that the presence of a short form of TET2 protein. 
This small peptide was recognized with Abcam (ab94580) antibody but not Active motif 
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(61389) antibody. Abcam antibody was generated by using 18aa long peptide inside 1-
50 aa length region of TET2. Active motif antibody was generated against a 
recombinant peptide corresponding to 1-300 aa of the full length peptide. We concluded 
that somehow active motif antibody was recognizing TET2 protein between 50-300 aa 
and the identified short form was not recognized because of this reason.  Our results 
stated that the truncated form of TET2 might be generated with Ca
+2
 dependent calpains 
and was even functional, though previously performed data argued that calpain mediated 
cleavage generated protein turnover instead of a truncated functional form of TET 
proteins [80]. To be certain about calpain cleavage, additional specific calpain inhibitors 
can be used in further experiments. Transfection experiments can be performed with tag 
containing TET2 vectors (such as HA-TET2 or Flag-TET2) and the cleaved TET2 
products can be analyzed with anti-tag antibodies. In addition to calpain cleavage, it 
might be possible that the identified short form of TET2 product might be a newly 
identified alternative spliced form. Since the short from is recognized with Abcam 
antibody, first 50 aa coding region can be cloned and transfection experiments can be 
performed to understand whether it is an alternative spliced form.  
In a study to show the DNA methylation events taking place in mouse neuronal 
differentiation, increase in 5hmC levels was together with loss of H3K27me3 and EZH2. 
For the first time the epigenetic  connection between 5hmC with histone marks and 
polycomb proteins was established [60]. We also showed in a similar way, increase in 
5hmC and gene expression levels were accompanied by decrease in EZH2 and 
H3K27me3 occupancies on the promoters of CT genes.     
 We looked into two different regions both containing a CT gene and a proximal 
non-CT gene which have differential gene expression in healthy and cancerous 
situations. Though they have different expression pattern, we identified that CT genes 
were controlled with DNA methylation whereas the proximal genes were not. Moreover 
the significant down-regulation of CT proximal genes in cancer was independent from 
promoter DNA methylation. From the literature, there were many examples that the 
gene expression may not associate with the DNA methylation status of the gene [81-83].  
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Since we identified that ALAS2 and CDR1 mRNA expressions existed in normal 
healthy colon and lung tissues, it is remarkable that promoters of 2 CT proximal gene 
were highly methylated in these tissues. Recently a new epigenetic mark, 5-
hydroxymethylcytosine (5hmC) was discovered (Kriaucionis and Heintz 2009; 
Tahiliani, Koh et al. 2009). 5hmC not only performs in DNA demethylation process but 
also is accepted as a unique epigenetic mark since it has its unique distribution pattern in 
the genome, inhibits the binding of 5mC binding proteins to DNA and has its own 
binding proteins (Shen and Zhang 2013). Because bisulphite sequencing method is 
insufficient to discriminate 5hmC from 5mC, we suggested that the identified 
methylated cytosines might be hydroxymetylated indeed. The results of 
hydroxymethylated DNA immunoprecipitation showed that promoters of ALAS2 and 
CDR1 had higher 5hmC contents compared to cancer cell lines. Though 5hmC presence 
was shown in healthy human tissues [51], for the first time we claimed that the gene 
expression was related with DNA hydroxymethylation in colon and lung tissues. The 
abundance of hydroxymethylated CT promoter proximal DNA in cancer cell lines and 
hydroxymethylated DNA of CT proximal genes in normal tissues stated that the function 
of TET enzymes was position specific. The expressions of TET enzymes justified this 
fact.  Locus specific role of TET enzymes were shown previously in concordance with 
our data [84].   
   To identify whether the highly homologous repeat regions covering CT genes 
have a role in concordant CT gene expression by forming a loop structure, we analyzed 
the gene expression in NY-ESO-1 repeat region. We included noncoding RNAs in the 
region in addition to protein coding genes IκBG and NY-ESO-1and to showed gene 
expression pattern inside and outside the repeat region was not coordinate. Even though 
Bredenbeck and her colleagues established the coordinate CT gene expression in 
MAGEA containing repeat [10], we believe the analysis of noncoding RNAs and genes 
other than CTs might be responsible from discrepancy between two studies.  Other 
repeat regions coding CT genes might be further investigated with a similar approach. In 
case of identification of a coordinate gene expression in repeat regions, additional 
experiments such as chromosome conformation capture can be performed to show the 3 
dimensional structure affecting the gene expression.      
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Finally, with the help of Caco-2 spontaneous differentiation model, we identified 
a window during EMT process and showed the dynamic expression of PAGE-2,-2B and 
SPANX-B genes by explaining the epigenetic mechanism behind it. (Figure 4 1).   
 
Figure 4 1: The proposed window of EMT and the suggested expression patterns of 
CT genes in EMT.  
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5 FUTURE PERSPECTIVES 
The detection of 5hmC in CT promoters and the association of 
hydroxymethylation with CT gene expression created new era for CT epigenetics. The 
information in relation to epigenetic of CT genes should be revised in this manner.  
Since the dynamic and reversible expression identified in the model was 
important for CT immunotherapy field, it is essential to mimic this differentiation in 
vivo as well. As an alternative approach, other hydroxymethylation agents such as 
Vitamin C or any differentiation agents could be analyzed to find out the induction of 
CT genes.  
Following functional studies about the truncated form of TET2 in order to 
identify the mechanism that it act or find out whether there are any other examples of 
this truncated form, is a necessity.  
 Performing analysis about miR-22 and miR-200 during Caco-2 spontaneous 
differentiation would be an interesting expansion of the project because the associations 
of EMT with miR-22, miR-200 and TET proteins were recently shown [85] 
In a very recent study colorectal cancer was classified in different subtypes 
representing to where the tumors belong in crypt villus axis and their responses to 
specific chemotherapeutic agents [86]. In parallel to this approach, Caco-2 
differentiation can be analyzed to find out whether this differentiation window matches 
with this classification. In addition to that, CT expression as a biomarker in different 
subtypes of colon cancer can also be investigated.   
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APPENDIX A 
Map and multiple cloning sites of vectors:  
pcDNA2.1:  
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pcDNA 4/TO:  
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pcDNA 6/TR:  
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pcDNA3,1/His/lacZ:  
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APPENDIX B 
Sequence of pcDNA 4/TO-ALAS2 
GACGGATCGGGAGATCTCCCGATCCCCTATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTA
AGCCAGTATCTGCTCCCTGCTTGTGTGTTGGAGGTCGCTGAGTAGTGCGCGAGCAAAATTTAAGCTACAAC
AAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTGCTTAGGGTTAGGCGTTTTGCGCTGCTTCGCGATG
TACGGGCCAGATATACGCGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTA
GTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAA
CGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGAC
GTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACG
CCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTT
TCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCA
ATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTG
TTTTGGAACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGG
TAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCTCCCTATCAGTGATAGAGATCTCCCTATCAGTG
ATAGAGATCGTCGACGAGCTCGTTTAGTGAACCGTCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGAC
CTCCATAGAAGACACCGGGACCGATCCAGCCTCCGGACTCTAGCGTTTAAACTTAAGCTTGGTACCGAGCT
CGGATCCACTTTAGGTTCAAGATGGTGACTGCAGCCATGCTGCTACAGTGCTGCCCAGTGCTTGCCCGGGG
CCCCACAAGCCTCCTAGGCAAGGTGGTTAAGACTCACCAGTTCCTGTTTGGTATTGGACGCTGTCCCATCC
TGGCTACCCAAGGACCAAACTGTTCTCAAATCCACCTTAAGGCAACAAAGGCTGGAGGAGATTCTCCATCT
TGGGCGAAGGGCCACTGTCCCTTCATGCTGTCGGAACTCCAGGATGGGAAGAGCAAGATTGTGCAGAAGGC
AGCCCCAGAAGTCCAGGAAGATGTGAAGGCTTTCAAGACAGATCTGCCTAGCTCCCTGGTCTCAGTCAGCC
TAAGGAAGCCATTTTCCGGTCCCCAGGAGCAGGAGCAGATCTCTGGGAAGGTCACACACCTGATTCAGAAC
AATATGCCTGGAAACTATGTCTTCAGTTATGACCAGTTTTTCAGGGACAAGATCATGGAGAAGAAACAGGA
TCACACCTACCGTGTGTTCAAGACTGTGAACCGCTGGGCTGATGCATATCCCTTTGCCCAACATTTCTCTG
AGGCATCTGTGGCCTCAAAGGATGTGTCCGTCTGGTGTAGTAATGATTACCTGGGCATGAGCCGACACCCT
CAGGTCTTGCAAGCCACACAGGAGACCCTGCAGCGTCATGGTGCTGGAGCTGGTGGCACCCGCAACATCTC
AGGCACCAGTAAGTTTCATGTGGAGCTTGAGCAGGAGCTGGCTGAGCTGCACCAGAAGGACTCAGCCCTGC
TCTTCTCCTCCTGCTTTGTTGCCAATGACTCTACTCTCTTCACCTTGGCCAAGATCCTGCCAGGGTGCGAG
ATTTACTCAGACGCAGGCAACCATGCTTCCATGATCCAAGGTATCCGTAACAGTGGAGCAGCCAAGTTTGT
CTTCAGGCACAATGACCCTGACCACCTAAAGAAACTTCTAGAGAAGTCTAACCCTAAGATACCCAAAATTG
TGGCCTTTGAGACTGTCCACTCCATGGATGGTGCCATCTGTCCCCTCGAGGAGTTGTGTGATGTGTCCCAC
CAGTATGGGGCCCTGACCTTCGTGGATGAGGTCCATGCTGTAGGACTGTATGGGTCCCGGGGCGCTGGGAT
TGGGGAGCGTGATGGAATTATGCATAAGATTGACATCATCTCTGGAACTCTTGGCAAGGCCTTTGGCTGTG
TGGGCGGCTACATTGCCAGCACCCGTGACTTGGTGGACATGGTGCGCTCCTATGCTGCAGGCTTCATCTTT
ACCACTTCTCTGCCCCCCATGGTGCTCTCTGGAGCTCTAGAATCTGTGCGGCTGCTCAAGGGAGAGGAGGG
CCAAGCCCTGAGGCGAGCCCACCAGCGCAATGTCAAGCACATGCGCCAGCTACTCATGGACAGGGGCCTTC
CTGTCATCCCCTGCCCCAGCCACATCATCCCCATCCGGGTGGGCAATGCAGCACTCAACAGCAAGCTCTGT
GATCTCCTGCTCTCCAAGCATGGCATCTATGTGCAGGCCATCAACTACCCAACTGTCCCCCGGGGTGAAGA
GCTCCTGCGCTTGGCACCCTCCCCCCACCACAGCCCTCAGATGATGGAAGATTTTGTGGAGAAGCTGCTGC
TGGCTTGGACTGCGGTGGGGCTGCCCCTCCAGGATGTGTCTGTGGCTGCCTGCAATTTCTGTCGCCGTCCT
GTACACTTTGAGCTCATGAGTGAGTGGGAACGTTCCTACTTCGGGAACATGGGGCCCCAGTATGTCACCAC
CTATGCCTGAGAAGCCAGCGGCCGCTCGAGTCTAGAGGGCCCGTTTAAACCCGCTGATCAGCCTCGACTGT
GCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTC
CCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGG
GGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGG
CTCTATGGCTTCTGAGGCGGAAAGAACCAGCTGGGGCTCTAGGGGGTATCCCCACGCGCCCTGTAGCGGCG
CATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCT
CCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCT
CCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCAC
GTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGA
CTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCC
GATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTAATTCTGTGGAATGT
GTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATT
AGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAAT
TAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTC
106 
 
TCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCTGCCTCTGAGCTATTCC
AGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTCCCGGGAGCTTGTATATCCATT
TTCGGATCTGATCAGCACGTGTTGACAATTAATCATCGGCATAGTATATCGGCATAGTATAATACGACAAG
GTGAGGAACTAAACCATGGCCAAGTTGACCAGTGCCGTTCCGGTGCTCACCGCGCGCGACGTCGCCGGAGC
GGTCGAGTTCTGGACCGACCGGCTCGGGTTCTCCCGGGACTTCGTGGAGGACGACTTCGCCGGTGTGGTCC
GGGACGACGTGACCCTGTTCATCAGCGCGGTCCAGGACCAGGTGGTGCCGGACAACACCCTGGCCTGGGTG
TGGGTGCGCGGCCTGGACGAGCTGTACGCCGAGTGGTCGGAGGTCGTGTCCACGAACTTCCGGGACGCCTC
CGGGCCGGCCATGACCGAGATCGGCGAGCAGCCGTGGGGGCGGGAGTTCGCCCTGCGCGACCCGGCCGGCA
ACTGCGTGCACTTCGTGGCCGAGGAGCAGGACTGACACGTGCTACGAGATTTCGATTCCACCGCCGCCTTC
TATGAAAGGTTGGGCTTCGGAATCGTTTTCCGGGACGCCGGCTGGATGATCCTCCAGCGCGGGGATCTCAT
GCTGGAGTTCTTCGCCCACCCCAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCA
CAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCT
TATCATGTCTGTATACCGTCGACCTCTAGCTAGAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTG
AAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCT
AATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGC
CAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTC
GCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATAC
GGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAAC
CGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACG
CTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCG
TGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCG
CTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCA
CGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGAC
ACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACA
GAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAA
GCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTTTTT
TTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGG
TCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCAC
CTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACA
GTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGA
CTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCG
AGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTG
GTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCA
GTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGC
TTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTA
GCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCA
CTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTC
ATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCAC
ATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCG
CTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAG
CGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTT
GAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATAC
ATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGA
CGTC 
 
Sequence of pcDNA 4/TO-CDR1 
GACGGATCGGGAGATCTCCCGATCCCCTATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTA
AGCCAGTATCTGCTCCCTGCTTGTGTGTTGGAGGTCGCTGAGTAGTGCGCGAGCAAAATTTAAGCTACAAC
AAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTGCTTAGGGTTAGGCGTTTTGCGCTGCTTCGCGATG
TACGGGCCAGATATACGCGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTA
GTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAA
CGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGAC
GTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACG
CCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTT
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TCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCA
ATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTG
TTTTGGAACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGG
TAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCTCCCTATCAGTGATAGAGATCTCCCTATCAGTG
ATAGAGATCGTCGACGAGCTCGTTTAGTGAACCGTCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGAC
CTCCATAGAAGACACCGGGACCGATCCAGCCTCCGGACTCTAGCGTTTAAACTTAAGCTTGGTACCGAGCT
CGGATCCATGGCTTGGTTGGAAGACGTGGATTTTCTGGAAGACGTACCTTTGTTGGAAGACATACCTTTGT
TGGAAGACGTACCTTTGTTGGAAGACGTACCTTTGTTGGAAGACACAAGTAGGCTGGAAGACATTAATTTG
ATGGAAGACATGGCTTTGTTGGAAGACGTGGATTTGCTGGAAGACACGGATTTCCTGGAAGACCTGGATTT
TTCGGAAGCTATGGATTTGAGGGAAGACAAGGATTTTCTGGAAGACATGGATAGTCTGGAAGACATGGCTT
TGTTGGAAGACGTGGACTTGCTGGAAGACACGGATTTCCTGGAAGACCCGGATTTTTTGGAAGCTATAGAT
TTAAGGGAAGACAAGGATTTTCTGGAAGACATGGATAGTCTGGAAGACCTGGAGGCCATTGGAAGATGTGG
ATTTTCTGGAAGACATGGCTTTTTTGGAAGACGTAGATTTTCAGGAAGACCCAAATTATCCGGAAGACTTG
GATTGTTGGGAAGACGTGGATTTTCTGGAAGACTGGGAGGTTACTGGAAGACATGGATTTTCTGGAAGACA
TGGATTTTCTGGAAGACGTGGATCTTCAGGAAGACATATATTGGCTGGAAGACCTGGATTTTTTCCGGAAG
ATGTGGATTGACTGGAAGACCTGGATTTGGTGGAAGACGTAGATTTTTCTGGAAGACACTGACTGACTGGA
AGACCTGGATTTCTTTCTGGAAGACACTGATTGACTGGAAGACCTGGATTTCTTTCTGGAAGACACTGATT
GACTGGAAGATCTAGGCGGCCGCTCGAGTCTAGAGGGCCCGTTTAAACCCGCTGATCAGCCTCGACTGTGC
CTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCC
ACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGG
TGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCT
CTATGGCTTCTGAGGCGGAAAGAACCAGCTGGGGCTCTAGGGGGTATCCCCACGCGCCCTGTAGCGGCGCA
TTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCC
TTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCC
CTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGT
AGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACT
CTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGA
TTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTAATTCTGTGGAATGTGT
GTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAG
TCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTA
GTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTC
CGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCTGCCTCTGAGCTATTCCAG
AAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTCCCGGGAGCTTGTATATCCATTTT
CGGATCTGATCAGCACGTGTTGACAATTAATCATCGGCATAGTATATCGGCATAGTATAATACGACAAGGT
GAGGAACTAAACCATGGCCAAGTTGACCAGTGCCGTTCCGGTGCTCACCGCGCGCGACGTCGCCGGAGCGG
TCGAGTTCTGGACCGACCGGCTCGGGTTCTCCCGGGACTTCGTGGAGGACGACTTCGCCGGTGTGGTCCGG
GACGACGTGACCCTGTTCATCAGCGCGGTCCAGGACCAGGTGGTGCCGGACAACACCCTGGCCTGGGTGTG
GGTGCGCGGCCTGGACGAGCTGTACGCCGAGTGGTCGGAGGTCGTGTCCACGAACTTCCGGGACGCCTCCG
GGCCGGCCATGACCGAGATCGGCGAGCAGCCGTGGGGGCGGGAGTTCGCCCTGCGCGACCCGGCCGGCAAC
TGCGTGCACTTCGTGGCCGAGGAGCAGGACTGACACGTGCTACGAGATTTCGATTCCACCGCCGCCTTCTA
TGAAAGGTTGGGCTTCGGAATCGTTTTCCGGGACGCCGGCTGGATGATCCTCCAGCGCGGGGATCTCATGC
TGGAGTTCTTCGCCCACCCCAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACA
AATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTA
TCATGTCTGTATACCGTCGACCTCTAGCTAGAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAA
ATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAA
TGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCA
GCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGC
TCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGG
TTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCG
TAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCT
CAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTG
CGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCT
TTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACG
AACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACAC
GACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGA
GTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGC
CAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTTTTTTT
108 
 
GTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTC
TGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCT
AGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGT
TACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACT
CCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAG
ACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGT
CCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGT
TAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTT
CATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGC
TCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACT
GCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCAT
TCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACAT
AGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCT
GTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCG
TTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGA
ATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACAT
ATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACG
TC 
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Abstract
Cancer-testis (CT) genes are expressed in various cancers but not in normal tissues other than in cells of the germline.
Although DNA demethylation of promoter-proximal CpGs of CT genes is linked to their expression in cancer, the
mechanisms leading to demethylation are unknown. To elucidate such mechanisms we chose to study the Caco-2
colorectal cancer cell line during the course of its spontaneous differentiation in vitro, as we found CT genes, in particular
PAGE2, -2B and SPANX-B, to be up-regulated during this process. Differentiation of these cells resulted in a mesenchymal-to-
epithelial transition (MET) as evidenced by the gain of epithelial markers CDX2, Claudin-4 and E-cadherin, and a concomitant
loss of mesenchymal markers Vimentin, Fibronectin-1 and Transgelin. PAGE2 and SPAN-X up-regulation was accompanied
by an increase in Ten-eleven translocation-2 (TET2) expression and cytosine 5-hydroxymethylation as well as the
disassociation of heterochromatin protein 1 and the polycomb repressive complex 2 protein EZH2 from promoter-proximal
regions of these genes. Reversal of differentiation resulted in down-regulation of PAGE2, -2B and SPANX-B, and induction of
epithelial-to-mesenchymal transition (EMT) markers, demonstrating the dynamic nature of CT gene regulation in this model.
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Introduction
Cancer-testis (CT) or cancer-germline genes are expressed in
tumors originating from various tissues, as well as in normal
germline and trophoblast cells, but are generally silent in other
normal tissues of the adult [1–3]. More than 100 different CT
genes can be grouped according to homology into families [2].
Despite the lack of sequence similarity between CT genes from
different families, re-expression of all CT genes in tumors has been
associated with demethylation of CpG residues within their
promoter-proximal regions [4]. This shared mechanism of
expression regulation is most likely the reason for their coordinate
expression in cancer [5–7]. However, the exact mechanism by
which DNA demethylation occurs at CT gene promoter-proximal
regions in cancers is unknown. CT genes show mostly a
heterogeneous expression pattern in tumors [8–10]; in contrast
to their expression in testis, which is demarcated and orderly [11].
A study in which stem-like and non-stem like cells of breast cancer
were selectively killed, revealed that CT gene expression is
generally a feature of more differentiated, non-stem cells [12].
Similarly, in melanoma, a subgroup of cells with more epithelial
features express CT genes, when cells with mesenchymal features
don’t [13]. Interestingly, melanoma cells can switch between these
two classes in vivo, suggesting that tumor heterogeneity, as defined
by CT gene expression, might represent a transitional phase
similar to the switch between epithelial and mesenchymal
phenotypes. Indeed, mesenchymal-to-epithelial transition (MET)
is associated with the induction of CT gene expression [14]. To
define mechanisms involved in regulating CT gene expression in
cancer and during MET, we chose to study the Caco-2
spontaneous differentiation model which demonstrates features
of MET and EMT during differentiation and de-differentiation,
respectively. Our data reveal that the dynamic regulation of the
two CT genes, PAGE and SPANX-B in this model system,
involves alterations of polycomb repressive complex 2 (PRC2) and
heterochromatin protein 1 (HP1) occupancy within their promot-
er-proximal regions, with concordant changes in TET expression
and cytosine hydroxymethylation (hmC) levels.
Methods
Cell lines, induction of differentiation and
de-differentiation
The Caco-2 cell line was obtained from the SAP Enstitusu
(Ankara, Turkey). HCT116 (colorectal) and Mahlavu (hepatocel-
lular) cancer cell lines were obtained from LGC Standards,
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Figure 1. Up-regulation of CT genes in parallel to MET in the Caco-2 SD model. Relative mRNA expression of CT genes (PAGE2, -2B and
SPANXB) (A), epithelial genes (E-cadherin (CDH1), claudin 4(CLDN4), CDX2) (B), and mesenchymal genes (fibronectin 1 (FN1), vimentin (VIM), transgelin
(TAGLN)) (C) as determined by quantitative PCR at days 0, 10, 20 and 30 post-confluence. Data represent average of two experiments. Change in
expression levels for all genes between days 0 and 30 is statistically significant (P,0.0001, by two way ANOVA with Tukey’s post hoc test).
doi:10.1371/journal.pone.0107905.g001
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Figure 2. SPANX-B and vimentin expression are mutually exclusive in differentiating Caco-2 cells. Immunofluorescent staining of
differentiating Caco-2 cells with DAPI counterstaining reveals a gradual increase in nuclear SPANX-B (green) with a concomitant decrease in
cytoplasmic vimentin expression (red); (206magnification) (A). Less than 1% of SPANX-B positive cells showed staining for vimentin on day 0 (B).
doi:10.1371/journal.pone.0107905.g002
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Middlesex, UK. A lung cancer cell line (SK-LC-17) was from the
Memorial Sloan Kettering Cancer Center, NY, USA. Caco-2 cells
were grown in EMEM and others in RPMI, supplemented with
20% FBS, 2 mM L-glutamine, 0.1 mM non-essential amino acids,
1.5 g/L sodium bicarbonate and 1 mM sodium pyruvate. All cell
culture media and supplements were purchased from Biochrom
AG, Berlin, Germany. The first day cells reached confluence was
designated day 0. Cells grown in parallel cultures were used to
determine phenotypic changes at days 0, 5, 10, 20 and 30, post-
confluence. Additional measures of differentiation for cells used in
this study have been reported elsewhere [15]. To induce
dedifferentiation, cells at the 20th day of differentiation were
detached and replated at about 50% confluence and RNA and
protein were harvested 5 days following replating.
In silico analysis of CT and EMT gene expression
Expression data contained within GSE1614 [16] was GC-RMA
normalized using GeneSpring v. 11.0. CT gene expression was
analyzed based on 31 probesets in corresponding to 23 CT genes
from 7 families (Figure S2). An interpretation was generated with
an entity list composed of EMT related genes as defined by
Loboda et al. [17], at three different time points. Genes for
validation were selected among those for which significant
differences of expression (p,0.05) was observed by one way
ANOVA test and Bonferroni FWER correction, when proliferat-
ing cells were compared to those at day 15.
Quantitative RT-PCR
Total RNA was isolated using the Trizol reagent (Ambion,
Foster City, CA, USA) and treated with DNAse I (Ambion, Foster
City, CA, USA). 200 ng of RNA was reverse transcribed using
Revert-Aid first strand cDNA synthesis kit (Thermo Fisher
Scientific, Boston, MA, USA). PCR reactions were performed
using an ABI 7500 thermal cycler (Applied Biosystems, Carlsbad,
CA, USA). All reactions were performed according to manufac-
turer’s recommendations. TaqMan Gene Expression Assays
(Applied Biosystems, Carlsbad, CA, USA) were used for the
following: GAPDH (4352934E), SPANX-B (Hs02387419_gH),
PAGE2 and -2B (Hs03805505_mH), GAGE (Hs00275620_m1),
SSX4 (Hs023441531_m1), NY-ESO-1 (Hs00265824_m1), and
MAGE-A3 (Hs00366532_m1). SYBR Green master mix with
ROX reference dye (Applied Biosystems, Carlsbad, CA, USA) was
used to determine CDH1, CDX2, CLDN4, VIM, FN1 and
TAGLN expression (Table S1). Cycling conditions for these
assays were 50uC for 2 min., 95uC for 10 min., followed by 40
cycles of 94uC for 15 sec., 60–65uC for 1 min. Relative expression
was calculated by the DDCt method [18]. All samples were
analyzed in triplicates and all experiments were repeated at least
twice.
Promoter methylation analysis
Genomic DNA was isolated by Proteinase K treatment,
following a phenol-chloroform extraction protocol. Bisulphite
treatment of 200 ng genomic DNA was performed using Zymo
DNA Methylation Gold Kit (Zymo Research, Irvine, CA, USA).
Bisulphite modified DNA was stored at 220uC and used for PCR
within 2 months. Two rounds of DNA amplification were
performed using One Taq Hot Start DNA polymerase (New
England Bioscience/NEB, Ipswich, MA, USA) using a Perkin
Elmer 9700 thermal cycler (Applied Biosystems, Carlsbad, CA,
USA). Primers used are given in Table S1. PCR products were
gel extracted using the QIAGEN gel extraction kit (Qiagen,
Hilden, Germany) and cloned into pCR2.1 (Invitrogen, Carlsbad,
CA, USA). Plasmid DNA was purified using the QIAprep Spin
Miniprep Kit (Qiagen, Hilden, Germany) from at least ten clones,
and sequence analyzed by IONTEK (Istanbul, Turkey).
5-hydroxymethyl cytosine analysis
Caco-2 genomic DNA (gDNA) was sheared by probe sonication
(30 sec. on, 30 sec. off, 5 cycles) to obtain 200–600 bp. fragments
assessed by 1% agarose gel electrophoretic analysis. Immunopre-
cipitation was performed using the hMEDIP kit (Abcam, Cam-
bridge, UK) according to manufacturer’s instructions. 5 pg of
control DNA was spiked into 500 ng of gDNA to use as an
internal control. Positive and negative controls of the kit were
included in all experiments. 2 ml from the eluted DNA was used as
template for quantitative RT-PCR using 2 X SYBR Green master
mix with ROX reference dye (Applied Biosystems, Carlsbad, CA,
Figure 3. Nuclear co-localization of CDX2 and SPANX-B in
differentiating Caco-2 cells. Immunofluorescent staining of differ-
entiating Caco-2 cells with DAPI counterstaining reveals overlapping
SPANX-B (Alexa Fluor 488: green) and CDX2 (Alexa Fluor 568: red)
expression; (206magnification) (A). More than 60 to 80% of the cells
show double-labeling when analyzed quantitatively (B).
doi:10.1371/journal.pone.0107905.g003
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USA) with the primers given in Tables S1 and S2. Primer
efficiencies were controlled. Cycling conditions were 50uC for
2 min., 95uC for 10 min. followed by 40 cycles of 94uC for 15 sec.,
60uC for 1 min. Shared genomic DNA was included in
quantitative RT-PCR to calculate % input.
Immunofluorescence microscopy
Cells attached to glass slides by centrifugation using the
Shandon CytoSpin3 (Thermo Scientific, Waltham, MA, USA)
were immediately fixed in 2% formaldehyde/PBS at room
temperature for 15 min. Fixed cells were permeabilized in 0.2%
Triton X-PBS for 10 min. followed by blocking with 1% BSA in
0.1% PBS-Tween for 1 hour. Incubations with the primary
antibody, diluted at 1:50, were performed overnight at 4uC.
Secondary antibody was added at 1:200, following washing in
0.1% PBS-Tween for 5 min. for 3 times, and incubated with cells
for 45 min. at room temperature (see Table S3 for the complete
antibody list). Stained samples were mounted with mounting
medium (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
containing DAPI solution. Cell lines used as positive controls were
Mahlavu (PAGE-2,-2B and SPANXB), MDA-MB 231 (VIM),
MCF-7 (TAGLN) and SW620 (CDX2, FN1). Negative controls
were combinations of primary antibodies with un-related second-
ary antibodies. All images were obtained using an AxioCam
MRc5 image capture device (Carl Zeiss, Oberkochen, Germany).
Western analysis
Cell lysates (extracted with RIPA buffer) separated on 4–12%
Novex Bis-Tris SDS gels (Invitrogen, Carlsbad, CA, USA) were
transferred to Immobilon-PSQ membranes (Millipore Corp.
Bedford, MA, USA) with an Invitrogen western blotting system
(Invitrogen. Carlsbad, CA, USA). Following blocking with 5%
milk powder in 0.02% PBS-T, blots were incubated with primary
antibody overnight at 4uC. Primary antibody dilutions were
1:1000 for CDX2, fibronectin, vimentin and transgelin, 1:2500 for
b-actin and 1:100 for SPANX-B and PAGE-2,-2B antibodies.
HRP conjugated secondary antibody (Abcam, Cambridge, UK)
was used at a 1:5000 dilution and incubated at room temperature
for 1 hour. Signals were detected using the ECL luminescence
assay (BioRad, Hercules, CA, USA).
Figure 4. Bisulfide sequencing of PAGE2, -2B and SPANX-B promoter-proximal regions. Filled and empty circles represent methylated and
unmethylated cytosines, respectively. %methylation within each analysed region, based on the 10 clones sequenced is indicated. CpG residues proximal
to PAGE2, -2B and SPANX-B promoters during Caco2 differentiation at days 0, 10 and 30 reveals no statistically significant change (by one-way ANOVA).
doi:10.1371/journal.pone.0107905.g004
Figure 5. Increased hydroxymethylation of PAGE2 and SPANX-B
during Caco-2 spontaneous differentiation. CHIP experiments
using an anti-hmC antibody and primers corresponding to +31 to +182
and +68 to +184 bp from the transcription start site of the PAGE2 and
SPANX-B genes, respectively. P values (one-way ANOVA) are 0.001 and
0.07 for PAGE2 and SPANX-B, respectively.
doi:10.1371/journal.pone.0107905.g005
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Chromatin Immunoprecipitation
Chromatin Immunoprecipitation (ChIP) was performed as
previously described [15]. Briefly, formaldehyde cross-linked cell
constituents were precipitated by proten A sepharose beads
coupled to antibodies against EZH2, HP-1 or H3K27m3 (Abcam,
Cambridge, UK), as well as isotype-specific control. Precipitated
DNA was amplified using primers specific for PAGE2, -2 or
SPANX-B promoter sequences (Tables S1 and S2), following
de-crosslinking.
Results
CT gene expression during Caco-2 spontaneous
differentiation (Caco-2 SD)
The undifferentiated colorectal cancer cell line Caco-2 under-
goes enterocytic differentiation upon reaching confluence in vitro
[19,20]. Gradual differentiation has been observed up to 30 days
post-confluence as evidenced by the up-regulation of various
differentiation-associated genes including sucrase-isomaltase, alka-
line phosphatase and carcinoembryogenic antigen (CEA), (Figure
S1) [15]. An in silico analysis of CT gene expression as defined by
31 probesets in the GSE1614 dataset, which contains gene
expression data for the Caco-2 SD model obtained during
differentiation (proliferating (2nd day), post-proliferation-undiffer-
entiated (8th day), and post-proliferation-differentiated (15th day))
[16], revealed modest up-regulation of almost all CT genes during
differentiation (Figure S2). We chose to validate the change in
expression of six CT gene/gene families by quantitative RT-PCR
in differentiating Caco-2 cells in vitro. GAGE, MAGE-A3, NY-
ESO-1 and SSX4 transcripts were undetectable on the first day of
confluence, as well as at later time points (data not shown).
However, significant up-regulation of PAGE2 (2 and 2B), and
SPANX-B genes was evident (Figure 1).
PAGE2 and SPANX-B expression follow MET in the Caco-2
SD model
Spontaneous differentiation of Caco-2 in vitro has been
reported to result in MET [21,22]. To determine if this occurred
in parallel to the up-regulation of PAGE2 and SPANX-B, we
analyzed the GSE1614 dataset for the expression of genes
representing EMT in colorectal cancer [17], and selected 6 genes
to be validated in our model. Analysis of mRNA and protein
expression of these revealed a decrease in mesenchymal genes
(vimentin, fibronectin 1 and transgelin) with a concomitant
increase in expression of epithelial genes (CDX2, claudin-4 and
E-cadherin) as the cells differentiated, demonstrating that the
increase in CT gene expression occurs simultaneously with MET
in this model (Figure 1 & Figure S3).
PAGE2, SPANX-B and EMT gene expression in situ
To study if the changes in protein expression of CT and EMT
genes occurred simultaneously in the same cells, we performed
double immunofluorescence staining during differentiation. A
gradual loss of mesenchymal markers was observed as cells
differentiated, with a concomitant increase in epithelial genes and
CT genes. SPANX-B and PAGE-2 were frequently co-expressed
with the epithelial marker CDX2 in the same cells but almost
never with VIM or FN1 (Figures 2, 3 and Figures S4, S5, S6,
S7).
PAGE2 and SPANX-B expression correlates with increased
hmC and ten-eleven translocation methylcytosine
dioxygenase (TET) up-regulation
Expression of all CT genes studied thus far including PAGE2
and SPANX-B have been associated with the demethylation of
CpG residues within regions proximal to the transcription start site
[1,2,23–26]. In this line, both PAGE2 and SPANX-B can be up-
regulated by 5-aza 29-deoxycytidine treatment (Figure S8).
Figure 6. TET expression during Caco-2 SD. mRNA of all three TET genes increase gradually during Caco-2 SD (A). An increase in only a 25 kD
version (B), but not the full-length TET2 protein (C) occurs simultaneously with the increase in mRNA. BAPTA-AM treatment results in a modest
decrease in the 25 kD TET2 protein, with the generation of a larger mw version (D). P values, as determined by one-way ANOVA, are 0.03, 0.01, and
0.07, for Tet1, Tet2, and Tet3, respectively.
doi:10.1371/journal.pone.0107905.g006
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However, bisulfite sequencing of promoter-proximal regions of
both PAGE2 and SPANX-B revealed no differences at different
stages of Caco-2 SD (Figure 4). As bisulfite sequencing is unable
to distinguish methyl cytosine (mC) from hmC, we asked whether
the change in CT gene expression could be related to altered
hmC/mC ratios within their promoters. In fact, chromatin
immunoprecipitation (ChIP) with a hmC specific antibody
revealed an increase in hmC during differentiation in both
PAGE2 and SPANX-B2 promoters (Figure 5). We next asked if
the increase in hmC was related to an increase in TET1, -2, and -3
expression as these proteins are responsible for converting mC to
hmC [27,28]. Indeed, the increase in hmC of PAGE2 and
SPANX-B2 promoters were correlated with an up-regulation of
TET2 mRNA expression, together with modest increases in TET1
and 3 (Figure 6A). Double immunofluorescence staining revealed
that the majority of cells expressing PAGE2 or SPANX-B were
positive for TET2 staining; indicating these two events occurred in
the same cells (Figure 7). It is therefore, likely that the increase in
TET2 expression causes increased hmC in these genes. Interest-
ingly, only a low molecular weight translation product (,25 kD) of
TET2 was increased in the differentiating cells, when no clear
difference in levels of the full-length TET2 protein was observed
(Figure 6B & C). The peptide used for generating the
commercial TET2 antibodies could specifically inhibit recognition
of the 25 kD product confirming its identity with TET2 (data not
shown). TET2 has recently been shown to undergo proteolytic
cleavage by calpain 1 and 2, generating a 25 kD product in vitro
[29]. To test if a cation-dependent protease is responsible for the
generation of the 25 kD protein, we treated differentiating cells
with an intracellular Ca2+ chelator (BAPTA-AM). This resulted in
Figure 7. Overlapping TET2 and CT gene expression in differentiating Caco-2 cells. Double immunofluorescence staining for TET2
(Alexafluor 568: red) and SPANX-B or PAGE2 (Alexafluor 488: green) with DAPI counterstaining 20 days post-confluence show overlapping nuclear
expression Magnification: 406 (A). More than 95% of cells expressing PAGE2 or SPANX-B were also positive for TET2 staining (B).
doi:10.1371/journal.pone.0107905.g007
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a modest reduction in the 25 kD TET2 protein with the
concomitant generation of a larger molecular weight product
(,50 kD), suggesting that the 25 kD TET2 protein is a Ca+2
dependent protease cleavage product with a 50 kD intermediate
(Figure 6D).
EZH2 and HP-1 occupancy of PAGE2 and SPANX-B
promoter proximal regions decrease during
differentiation
Hydroxymethylation has been reported to prevail in promoters
with dual H3K4 and H3K27 trimethylation that also bind PRC2
proteins [30]. The PRC2 complex protein EZH2 has been implied
in the repression of GAGE, another CT gene [31]. We therefore,
asked whether increased hmC within CT gene promoters resulted
in altered EZH2 binding to the same sites. Indeed, ChIP
experiments demonstrated a decrease in EZH2 occupancy, as
well as a decrease in H3K27m3 in both PAGE2 and SPANX-B
promoters during Caco-2 SD (Figure 8). The PRC2 component
SUZ12 has been reported to regulate H3K9 methylation and in
turn, heterochromatin protein 1 (HP1a) binding. In fact, we
observed a simultaneous decrease in HP1 binding to both PAGE2
and SPANX-B promoters during differentiation, that correlated
with PAGE2 and SPANX-B upregulation (Figure 8). Thus, our
data suggest that both PRC2 and HP-1 contribute to maintaining
PAGE2 and SPANX-B in a transcriptionally silent state when the
Figure 8. Chromatin modifications within PAGE2 and SPANX-B during Caco-2 differentiation. CHIP analysis of PAGE2, -2B and SPAN-X
transcription-start site-proximal regions reveals decreased EZH2 occupancy and H3K27m3 (A), as well as decreased HP-1 binding during
differentiation (B). P values (one-way ANOVA) calculated for PAGE2B, PAGE2, and SPANX-B, are ,0.001, 0.02, and 0.001 for EZH2; 0.003, ,0.001, and
,0.0001 for H3K27m3; and 0.001, ,0.001, and ,0.001, for HP1, respectively.
doi:10.1371/journal.pone.0107905.g008
Figure 9. De-differentiation induced EMT and down-regulation of CT and TET genes. De-differentiation induced by growth under non-
confluent conditions indicated by decreased sucrose isomaltase (SI) mRNA levels (A), leads to down-regulation of CDX2, PAGE2, -2B and SPANX-B, with
concomitant up-regulation of TGLN (B). TET1 and -2 mRNAs are also down-regulated during de-differentiation (C).
doi:10.1371/journal.pone.0107905.g009
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cells have a mesenchymal phenotype, and that increased TET2
expression and hmC mediated transcriptional activation are
related to PRC2 and HP-1 dissociation from the promoters of
these CT genes during differentiation.
PAGE2 and SPANX-B up-regulation is reversed during EMT
We hypothesized that if the epigenetic alterations underlying
CT gene expression happened in parallel to MET, that this
process could be reversed if cells entered EMT. To test this
hypothesis, differentiated Caco-2 cells were detached and allowed
to proliferate for 5 days. This resulted in their rapid de-
differentiation as evidenced by down-regulation of SI. De-
differentiated cells down-regulated PAGE2 and SPANX-B, as
well as CDX, as they up-regulated TAGLN, in line with ongoing
EMT (Figure 9). Although transcription of all three TET genes
decreased during de-differentiation (Figure 9), we did not observe
a decrease in hmC during this period (data not shown). We,
therefore, conclude that the up-regulation of CT gene expression
is reversible in this model.
Discussion
Previous studies revealed that CT gene expression correlated
with an epithelial rather than a mesenchymal phenotype, and
showed the up-regulation of CT genes during MET [12,14]. To
our knowledge, this is the first report describing alterations in
several epigenetic mechanisms within promoters of two CT genes
during MET-like differentiation concordant with a dynamic
change in gene expression. As bisulfite sequencing of PAGE2
and SPANX-B promoters revealed no change upon differentia-
tion, the increased hmC must strictly involve methylated CpG
residues. This is in line with the fact that TET enzymes are
responsible for the conversion of 5-methyl cytosine to 5-
hydroxymethyl cytosine [27,28]. Conversion of hmC to mC is a
far more complex process and might not happen with similar
kinetics [32,33]. This is likely the reason why we did not observe a
change in hmC during the 5 day de-differentiation process of
Caco-2 cells despite the decrease observed in global TET levels.
Our finding that PAGE2, SPANX-B and TET2 induction is
reversible is similar to another study in embryonic stem cells where
Vitamin C was shown to induce TET2 expression, which in turn,
resulted in up-regulation of CT genes. Both events were reversible
upon Vitamin C withdrawal [34].
Although hydroxymethylation within gene promoters has been
reported to decrease during differentiation of normal cells, a recent
study revealed that about 20% of all modified cytosines in most
CT genes in human brain, where they are not expressed, consist of
hmC [35]. Up-regulation of TET2 expression in cancer has been
associated with MET [36,37]; and therefore, a more differentiated
state [30]. Similar to the inverse correlation between EZH2 and
CT/TET2 expression we report here, others have shown EZH2
and TET enzymes to repress and induce differentiation of
neuronal precursors, respectively [38]. CT genes are up-regulated
during the initial stages of development in the human embryo, but
decrease as tissues differentiate further [39]. As adult colon tissue
does not show PAGE2 or SPANX-B expression (data not shown),
had Caco-2 cells the capability of differentiating further, both
genes might have been down-regulated completely. On the other
hand, the fact that we could not demonstrate up-regulation of
GAGE, MAGE-A3, NY-ESO-1 or SSX4 expression in this model
might be because these genes are expressed at earlier stages of
differentiation. We believe this because SPANX-B expression is
primarily in post-meiotic cells of the testis (i.e. spermatocytes,
spermatids, or sperm), whereas GAGE, MAGE-A3, NY-ESO-1 or
SSX expression is primarily in spermatogonia [11].
Our data and that of several others’ indicate that cancer cells
that express CT genes have more of an epithelial rather than a
mesenchymal phenotype. We suggest that CT genes PAGE2 and
SPANX-B are induced during a window of differentiation that
correlates with up-regulation of epithelial markers of differentia-
tion. The Caco-2 SD model has made it possible to observe the
actively changing epigenetic landscape within the promoters of
these CT genes. However, as CT gene expression in tumors has
closely been related to the methylation state of their promoter, the
process that leads to CT gene induction in vivo might ultimately
result in ‘‘fixing’’ of the epigenetic state which would in turn result
in CpG methylation. Yet, via dynamic MET in tumors [40], it is
conceivable that even this might change over the course of the
disease.
From a clinical perspective, data from our lab as well as from
others reveal that sub-grouping of tumors based on gene
expression profiles can clearly identify cells with different chemo-
sensitivity profiles [12,41,42]. In this line, we predict future studies
will reveal distinct drug sensitivity profiles for colorectal cancer
subtypes as possibly defined by PAGE2 and SPANX-B expression,
for which the Caco-2 SD model could be used.
Supporting Information
Figure S1 Post-confluence differentiation of Caco-2 in
vitro. Up-regulation of sucrase-isomaltase (A), and carcinoem-
bryonic antigen (CEA) (B) in cells collected at indicated days post
confluence (DPC) as determined by quantitative RT-PCR, and
Western analysis, respectively. Alkaline phosphatase expression is
also upregulated as determined by immunohistochemistry reveal-
ing differentiation (C). Other measures of differentiation for the
cells used in this study have been reported previously (ref. 17).
*P,0.001 (ANOVA with Tukey’s post hoc test).
(DOCX)
Figure S2 Up-regulation of CT gene expression during
Caco-2 spontaneous differentiation in vitro. Heat map
based on 31 probesets in GSE1614 corresponding to 23 CT genes
from 7 families. As compared to proliferating cells, gene expression
incrementally increases in at confluence (8th day) and further
during post-confluence differentiation (15th day).
(DOCX)
Figure S3 Western analysis of differentially expressed
genes during Caco-2 SD. A gradual increase in SPANX-B and
CDX2 in parallel to a decrease in expression of FN, VIM and
TGLN up to day 30 post-confluence. Results from 3 independent
differentiation experiments are shown.
(DOCX)
Figure S4 SPANX-B and Fibronectin expression show
limited overlap in differentiating Caco-2 cells. Immuno-
fluorescent staining of differentiating Caco-2 cells with DAPI
counterstaining reveals a gradual increase in nuclear SPANX-B
(Alexa Fluor 488: green) with a concomitant decrease in
cytoplasmic fibronectin expression (Alexa Fluor 568: red); (206
magnification) (A). Less than 10% of cells expressing SPANX-B
stained for fibronectin at day 0 (B).
(DOCX)
Figure S5 PAGE2, -2B and Vimentin expression are
mutually exclusive in differentiating Caco-2 cells. Immu-
nofluorescent staining of differentiating Caco-2 cells with DAPI
counterstaining reveals a gradual increase in nuclear PAGE2, -2B
(Alexa Fluor 488: green) with a concomitant decrease in
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cytoplasmic vimentin expression (Alexa Fluor 568: red); (206
magnification) (A). Less than 10% of cells showed double
fluorescence when staining was analyzed quantitatively at day 0.
At later time points, none of the cells showed double staining (B).
(DOCX)
Figure S6 PAGE2, -2B and fibronectin expression are
mutually exclusive in differentiating Caco-2 cells. Immu-
nofluorescent staining of differentiating Caco-2 cells with DAPI
counterstaining reveals a gradual increase in nuclear PAGE2, -2B
(Alexa Fluor 488: green) with a concomitant decrease in
cytoplasmic fibronectin expression (Alexa Fluor 568: red); (206
magnification) (A). Less than 15% of cells showed double
fluorescence when staining was analyzed quantitatively at day 0
(B).
(DOCX)
Figure S7 Nuclear co-localization of CDX2 and PAGE2,
-2B in differentiating Caco-2 cells. Immunofluorescent
staining of differentiating Caco-2 cells with DAPI counterstaining
reveals overlapping PAGE2. -2B (Alexa Fluor 488: green) and
CDX2 (Alexa Fluor 568: red) expression; (206magnification) (A).
More than 80% of the cells show double-labeling when analyzed
quantitatively (B).
(DOCX)
Figure S8 Induction of PAGE2,-2B and SPANX-B gene
expression by 5-aza-29-deoxycytidine in HCT116 (top)
and SK-LC-17 cell lines (bottom). Relative mRNA expres-
sion values at indicated time points compared to day 0, as
determined by quantitative RT-PCR are shown.
(DOCX)
Table S1 PCR primers.
(DOCX)
Table S2 Primer locations.
(DOCX)
Table S3 Antibodies used for IF staining and western
blot analysis.
(DOCX)
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